Human Cloning: Is the Reach of FDA Authority Too
Far a Stretch? *
Gregoyj Rokosz
INTRODUCTION

On July 5, 1996, Dolly the sheep was born at the Roslin Institute
in Scotland' and became the first offspring born as the result of the
transfer of genetic material from a differentiated adult cell to an
enucleated, unfertilized egg.2 This somatic cell nuclear transfer
technique3 resulted in the first successful cloning of an adult

mammal.4 In essence, Dolly, possessing the genetic makeup of only
one parent, became the delayed genetic twin of an adult sheep.5 The
idea that human cloning might now be possible ignited global debate
regarding the moral, scientific, and medical ramifications of such a
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I See National Bioethics Advisory Comm'n, CLONING HuMAN BEINGS: REPORT AND
RECOMMENDATIONS OF THE NAT'L BIOETHICS ADVISORY COMM'N

NBAC REPORT].

1 (1997) [hereinafter

2 See Ian Wilmut et al., Viable Offspring Derived from Fetal and Adult Mammalian
Cells, NATuRE, Feb. 27, 1997, at 810. The cell nucleus containing the genetic material
was transferred to the enucleated egg from an adult sheep mammary gland cell. See
id.
3 See NBAC REPORT, supra note
1, at 1.
4 See Kenton Abel, Biotechnology and Medical Devices: State Legislation: 1997
California Legislative Service 688 (West) - Human Cloning, 13 BERKELEY TECH. L.J. 465,
465 (1998).
5 See NBAC REPORT, supranote 1,
at 1.
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prospect.6
Subsequent to the publication of the successful cloning of a
sheep by researchers at the Roslin Institute, President Clinton
implemented a ban on federal funding for human cloning
experiments
The President also charged the National Bioethics
Advisory Commission (NBAC) with the task of analyzing the legal and
ethical issues concerning human cloning and of reporting its
recommendations within ninety days.' Shortly after Dolly's birth
announcement, legislative proposals to ban human cloning were
introduced at both the state9 and federal levels.'0

When momentum for such a ban seemed to lessen," Chicago
physicist Richard Seed announced at a December 1997 scientific

symposium that he was ready, willing, and able to clone humans as
soon as he procured the necessary funding. 2 Seed's proclamations
6 See Ian Wilmut, Dolly's False Legacy, TIME, Jan.
11, 1999, at 74.
7 See NBAC REPORT, supra note 1, at 3; WilliamJ. Clinton,

Speech Regarding the
Prohibition on Federal Funding for Cloning of Human Beings, in 33 WEEKLY COMP.
PREs. Doc. 281 (Mar. 4, 1997). Unlike the ban on federal funding of human embryo
research instituted in December 1994, the prohibition of federal funding for human
cloning research would apply to all federal agencies. See id.
8 See NBAC REPORT, supra note
1, at 3.
9 See Abel, supra note 4, at 466 n.7 (citing state bills S. 511, 1997
Leg., Reg. Sess.
(Ala. 1997); A.B. 1082, 1997 Leg., Reg. Sess. (Ala. 1997); S.J.R 14, 1997-98 Leg., 1st
Sess. (Cal. 1997); S.C.R. 39, 1997-98 Leg., lstSess. (Cal. 1997); S. 1344, 1997-98 Leg.,
1st Sess. (Cal. 1997) (enacted); A.B. 1251, 1997-98 Leg., 1st Sess. (Cal. 1997); H.B.
1237, 1997-98 Leg., 1st Sess. (Fla. 1997); H.B. 2235, 90th Leg., 1st Sess. (Ill. 1997);
H.B. 1829, 90th Leg., 1st Sess. (Ill. 1997); S. 134, 118th Leg., 1st Sess. (Me. 1997);
H.J.R. 28, 1997-98 Leg., 1st Sess. (Md. 1997); H.B. 4846, 89th Leg., 1st Sess. (Mich.
1997); H.B. 4962, 89th Leg., 1st Sess. (Mich. 1997); H.B. 824, 89th Leg., 1st Sess.
(Mo. 1997); A.B. 2849, 207th Leg., Reg. Sess. (N.J. 1997); S. 2877, 220th Leg., Reg.
Sess. (N.Y. 1997); A.B. 5383, 220th Leg., Reg., Sess. (N.Y. 1997); S. 782, 1997-98 Leg.,
1st Sess. (N.C. 1997); S. 1017, 69th Leg., 1st Sess. (Or. 1997); H.B. 3617, 112th Leg.,
1st Sess. (S.C. 1997); S. 410, 73rd Leg., 1st Sess. (W. Va. 1997)).
10 See id. at 466 n.6 (citing federal bills S. 368, 105th Cong. (1997); H.R. 922,
105th Cong. (1997); H.R. 923, 105th Cong. (1997)). In addition, President Clinton
suggested legislation that would ban all human cloning for a period of five years,
exclusive of cell or tissue cloning and consistent with NBAC guidelines. SeeJoanne
Silberner, Seeding the Cloning Debate; Richard Seed; Capital Report, THE HASTINGS CTR.
REP., Mar. 13, 1998, at 5. The President's proposal, however, failed to progress for
want of a legislative sponsor. See id
I See Gina Kolata, On Cloning Humans, "Never" Turns Swiftly into "Why
Not," N.Y.
TIMES, Dec. 2, 1997, at Al.
12 See Silberner, supra note 10, at 5. On January 6, 1998,
Seed stated on National
Public Radio: "We are going to have almost as much knowledge and almost as much
power as God .... Cloning and the reprogramming of DNA is the first serious step
in coming to one with God." Id. Because of the medical risks associated with human
cloning, Seed later said that he decided to clone himself first. See Richard Saltus,
Would-Be Cloner Plans to Start with Himself, BOSTON GLOBE, Sept. 6, 1998, at A6. Seed
was also quoted as saying that "'clones would be 'fun' and would unleash a 'torrent of
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rekindled the human cloning debate"5 and precipitated another
round of legislative proposals to ban human cloning.14
Such
sentiment was not limited to the United States, and many nations
research'... [and] would be the first step toward discovering immortality.'" Id.He
predicted that his Chicago clinic would achieve success with human cloning within
two and one-half years. See id
13 See Silberner, supra note 10, at 5; see alsoJohn A. Robertson, Human
Cloning and
the Challenge of Regulation, 339 NEW ENG.J. MED. 119, 121 (1998) (noting that profitmotivated entrepreneurs such as Seed are unlikely to have many customers until the
safety of cloning is ensured); George J. Annas, Why We Should Ban Cloning, 339 NEW
ENG. J. MED. 122, 125 (1998) (commenting on the increased public discussion and
legislative activities following Seed's announcements); Mara Bovsun, GOP Human
Cloning Bill Bumped Off Fast Track by Senate Vote, BIoTEcH. NEWSWATCH, Feb. 16, 1998,
at 1 (recognizing that "[t]he rush to get a cloning bill passed was spurred by...
maverick scientist Richard Seed"); Kathleen Fackelmann, CloningDebate Erupts Anew:
Bill Clinton Denounces a Plan Announced by Physicist Richard Seed to Open a Fertility Clinic
for Human Cloning, 153 Sci. NEws, Jan. 24, 1998, at 59 (noting the FDA's assertion of
regulatory authority over human cloning research); Deborah Josefson, US. Scientist
Plans Human Cloning Clinic, 316 BRrr. MED. J. 167, 167 (1998) (discussing Seed's
effect on the congressional timetable for cloning legislation and suggesting a causal
relationship between Seed's actions and an emergency meeting of the NBAC).
Following Seed's statements, White House Press Secretary Mike McCurry declared
that Seed would be "irresponsible, unethical, and unprofessional" if he was to carry
out his intentions. Id Donna Shalala, Secretary of the Department of Health and
Human Services (HHS), said "that the Food and Drug Administration has the
authority to regulate human cloning in the meantime." Id.Richard Seed has stated
that he would open a human cloning clinic in another country if such activities were
banned in the United States, that he has already discussed this possibility with
Mexican officials, and that he has already identified a team of doctors, laboratory
researchers, and four infertile couples willing to proceed should he obtain the
necessary funding. See id.
14 SeeAbel, supra note 4, at 466 n.12 (citing federal legislative
proposals S.1574,
105th Cong. (1998); S.1599, 105th Cong. (1998); S.1601, 105th Cong. (1998); S.
1602, 105th Cong. (1998); S. 1611, 105th Cong. (1998); H.R. 3133, 105th Cong.
(1998)). State legislatures have also debated similar issues. See Abel, supra note 4, at
466 n.13 (citing state bills S.8, 1998 Leg., Reg. Sess. (Ala. 1998); S.68, 1998 Leg.,
Reg. Sess. (Ala. 1998); S.J.R. 6, 1998 Leg., Reg. Sess. (Ala. 1998); H.B. 5475, 1998
Leg., Reg. Sess. (Conn. 1998); S.241, 139th Leg., 2d Sess. (Del. 1998); H.B. 1508,
144th Leg., 2d Sess. (Ga. 1998); S.1230, 90th Leg., 2d Sess. (Ill. 1998); S.1243, 90th
Leg., 2d Sess. (Ill. 1998); S.411, 110th Leg., 2d Sess. (Ind. 1998); H.B. 3206, 19th
Leg., 2d Sess. (Haw. 1998); H.B. 2846, 77th Leg., 2d Sess. (Kan. 1998); H.J.R. 11,
1998 Leg., Reg. Sess. (Md. 1998); S.864, 89th Leg., 2d Sess. (Mich. 1998); H.B. 5475,
89th Leg., 2d Sess. (Mich. 1998); H.R. 197, 89th Leg., 2d Sess. (Mich. 1998); H.B.
198, 89th Leg., 2d Sess. (Mich. 1998); H.C.R1 80, 89th Leg., 2d Sess. (Mich. 1998);
H.B. 2730, 80th Leg., 2d Sess. (Minn. 1998), S.2423, 80th Leg., 2d Sess. (Minn.
1998); H.B. 996, 1998 Leg., Reg. Sess. (Miss. 1998); H.B. 1658, 155th Leg., 2d Sess.
(N.H. 1998); A.B., 329, 208th Leg., Reg. Sess. (N.J. 1998); S.5993, 221st Leg., Reg.
Sess. (N.Y. 1998); A.B. 9116, 221st Leg., Reg. Sess. (N.Y. 1998); S.218, 122d Leg., 2d
Sess. (Ohio 1998); H.B. 675, 122d Leg., 2d Sess. (Ohio 1998); H.B. 2128, 182d Leg.,
2d Sess. (Pa. 1998); H.B. 7123, 1997-98 Leg., 2d Sess. (R.I. 1998); S.2208, 100th Leg.,
2d Sess. (Tenn. 1998); S.2295, 100th Leg., 2d Sess. (Tenn. 1998); H.B. 2198, 100th
Leg., 2d Sess. (Tenn. 1998); H.B. 2281, 100th Leg., 2d Sess. (Tenn. 1998); A.B. 769,
93d Leg., 2d Sess. (Wis. 1998); H.B. 752, 1998 Leg., Reg. Sess. (Va. 1998)).
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called for an international ban on human cloning projects. 5 Dr.
Seed's declarations also touched off an assault against his movement
by the medical community. 6 Carl B. Feldbaum, president of the
Biotechnology Industry Organization (BIO), sought the assistance of
Donna Shalala, Secretary of the Department of Health and Human
Services (HHS), to support the assertion
of FDA authority and
7
jurisdiction over human cloning attempts.
SeeAbel, supra note 4, at 467 nn.14-15. On January 12, 1998, French President
Jacques Chirac called for a human cloning ban before a European conference of
national ethics committees. See id Nineteen out of forty nation members of the
Council of Europe signed a treaty on January 12, 1998 to ban human cloning, and in
so doing declared that human cloning is "contrary to human dignity and thus
constitutes a misuse of biology and medicine." Id. Signatory nations included
Denmark, Estonia, Finland, France, Greece, Ireland, Italy, Latvia, Luxembourg,
Macedonia, Moldavia, Norway, Portugal, Romania, San Marino, Slovenia, Spain,
Sweden, and Turkey. See id. England declined to sign the treaty, finding the it too
strict, while Germany declined on the basis that it was too liberal. See id Pope John
Paul II likewise advocated a ban on human cloning. See id
16 See Opposition Grows to Human Cloning on Bioethics Premise,
MED. INDus. TODAY,
Jan. 15, 1998.
17 See id
The Biotechnology Industry Organization (BIO) also endorsed
President Clinton's initiatives and the moratorium recommended by the NBAC. See
id. Carl B. Feldbaum opined that the "'recognition and assertion of the FDA's
regulatory power over human cloning will protect biomedical advances, and at the
same time will give everybody some breathing room to debate this issue.'" Id.
Feldbaum emphasized the experimental nature of cloning in correspondence to
HHS by noting that there were 276 unsuccessful cloning attempts prior to the birth
of Dolly. See id. The BIO posited that the FDA's authority to regulate biological
products might very well encompass human cloning attempts. See id An FDA source
has been quoted as saying that "not only does the agency believe it has the authority
to regulate attempts at human cloning, it is prepared to do so with a view toward
protecting the public health." See Lisa Seachrist, BIO Says Human Cloning Falls Under
FDA's Purview, BIowoRLD TODAY, Jan. 15, 1998. Feldbaum opined that the FDA has
broad power to regulate biologic products under a regulatory framework for cellular
and tissue-based products promulgated in February 1997. See id. Noting that this
framework regulates tissue-based products based on the amount of cellular or tissue
manipulation, Feldbaum postulated that somatic cell nuclear transfer cloning
techniques involving more than minimal manipulation would fall within the FDA's
regulatory authority and would require both investigational new drug (IND)
applications and license review. See id The BIO further asserted:
The FDA not only regulates tissues and manipulated cells, but has the
authority to regulate nucleic acid used in humans and regulates many
of the medical devices that would be used to produce a human clone..
• . [T]he FDA is prepared to use tissue and biologics regulations to
assert its authority to review any protocols that attempt to clone a
human being.
In deciding whether to approve any cloning IND, the agency would
seek to ensure that preclinical and animal data were sufficient to
indicate the safety and efficacy of the procedure. The FDA could issue
clinical holds on protocols, disqualify investigators who make attempts
in spite of a clinical hold, or go to the courts to enjoin such individuals
15

468

SETON HALL LAWREVIEW

[Vol. 30:464

On the heels of this public debate, and sparked in part by
Richard Seed's public declarations of his intent to clone human
beings, the FDA announced in January 1998 that it had statutory
authority to regulate human cloning.
The FDA determined that
"manipulated" cells and nucleic acids constitute biologic products,
thus placing cloning technology under the agency's jurisdiction
pursuant to its tissue-product regulations. 9 The agency asserted that
any attempts at human cloning would necessitate the filing of an
Investigational New Drug (IND) application.20
The FDA also
from cloning a human being.
Id. Feldbaum emphasized that neither the safety nor the efficacy of cloning
technology has been established and concluded that a clinical hold should be placed
on any IND application for human cloning. See id.For a discussion concerning FDA
guidance documents and an FDA-proposed rule regarding regulation of cellular and
tissue-based products as biological products, see infra notes 173-77 and
accompanying text.
is See F.D.C. Reports, 60 "The Pink Sheet" No. 3, Jan. 19, 1998 at T&G1.
The
FDA maintained that violations of agency regulations would be judicially enforced
under the Public Health Service Act, 42 U.S.C. § 212 (1994). See id.Lead Deputy
Commissioner Michael Friedman, M.D. was quoted on National Public Radio's
January 12, 1998 DianeRehm Show as saying"We believe we have jurisdiction over this, and before an investigational
procedure can go forward, it needs our review and approval ....We all
think that this is a technology that is enormously promising for
animals, for plants and for other kinds of situations .... [W]e would
not prohibit this activity, but we would ask for the scientific data that
shows it is safe, that there is adequate expertise behind it, that the
facilities are satisfactory [and] that the individuals involved have the
proper experience and training . . . . [T]he general scientific
community is very uncomfortable with the idea of moving forward
right now. At least our agency certainly agrees with that, and the
Secretary of HHS has said that."
Id.Friedman acknowledged that although exercise of FDA regulatory authority over
cloning would enable the agency to "'put the brakes on cloning efforts, [it would
also] create a regulatory pathway for potential future approval of the technology.'"
F.D.C. Reports, 24 "The Gray Sheet" No. 3,Jan. 19, 1998 at I&W8; see also Rick Weiss,
Human Clone Research Will Be Regulated; FDA Asserts It Has Statutory Authority to Regulate
Attempts at Human Cloning, WASH. POST, Jan. 20, 1998, at Al (quoting Lead Deputy
Commissioner Friedman's assertions of FDA jurisdiction under the FFDCA and
statements of agency resolve to assert regulatory authority over cloning). Freidman
represented that "serious health and safety issues" for both the mother and fetus
were implicated by the kinds of manipulations inherent in human cloning
procedures. See id.
19 See F.D.C. Reports 60, "The Pink Sheet" No. 3, Jan.
19, 1998 at T&G1. Philip
D. Noguchi, Director of FDA's cellular and gene therapy division, announced that
the agency has firmly decided that "more than minimal manipulation" of human
cells is involved in human cloning and that this standard "is the dividing line
between human tissue experiments that do and do not require prior approval from
the FDA." Weiss, supra note 18, at Al; see also infra notes 165-69, 171-77 and
accompanying text (discussing FDA regulation of cellular and tissue-based products).
20 See Weiss, supra note 18, at Al. Prospective cloners
would need to comply with
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asserted, in an October 26, 1998 "Dear Colleague" letter, that the
agency has regulatory jurisdiction "over clinical research using
cloning technology to create a human being"2 pursuant to the Public
Health Service Act (PHSA)2 and the Federal Food, Drug, and
Cosmetic Act (FFDCA).23 Interestingly, Richard Seed reported that
he would now need to decide "whether to challenge the FDA's legal
interpretation [s] or simply move his cloning effort out of the
country.,1
Considerable debate has since arisen as to whether the reach of
FDA authority, which usually encompasses regulation of drugs and
therapies for the treatment of disease, can be stretched to cover
human cloning. 5 Three possible theories have been advanced to
a formal IND application procedure similar to that required of drug companies
when they seek to test new medicines. See id. The FDA would undertake a lengthy
review and cloning researchers would need to convince the agency that the proposed
protocols do not create an unreasonable risk of harm to human subjects. See id.
Given the extremely high failure rate in animal cloning attempts, researchers would
find it difficult to comply with agency mandates on safety and public hearings that
might be required each time a human cloning proposal is evaluated. See Cloning:
FDA Will Regulate Procedures,HEALTH LIN,Jan. 20, 1998.
21 See Letter from Stuart L. Nightingale,
M.D., Associate Commissioner,
Department of Health and Human Services (Oct. 26, 1998) (on file with the Seton Hall
Law Review). The agency asserted that under the FFDCA, the PHSA, and the FDA's
implementing regulations, any human cloning researcher must submit an IND to the
FDA before commencing such experimentation. See id In addition, the FDA
requires a research plan description, an authorization from a properly constituted
and functioning Institutional Review Board (IRB), and informed consent from all
human research subjects. See id. The FDA would not permit any such studies to
proceed until all major unresolved safety questions have been answered. See id.The
agency noted that "[tithe procedures and requirements governing the use of
investigational new drugs, including those for the submission and review of IND[ ],
are set forth in Title 21 of the Code of Federal Regulations (CFR), Part 312." I&
Compliance with IRB requirements is set forth in 21 C.F.R. Part 56. See it
42 U.S.C. § 262 (a) (1994).
22 21 U.S.C. § 321 (a)
(1994).
24 Feds: Cloning is
Regulated, FDA Says Procedure Requires Approval, NEWSDAY (New
York),Jan. 21, 1998, at A20.
25 See Sheryl Gay Stolberg, F.D.A. Stand on Cloning Raises Even More Questions,
N.Y.
TIMES, Jan. 21, 1998, at A14. "While agency officials insist they have jurisdiction,
some experts in food and drug law - as well as [ ] Congressman [Ehlers] who
proposes to ban the cloning of people - said they were not so certain." Id.
Representative Vernon J. Ehlers, a Michigan Republican, opined that classifying
cloning procedures as drugs would be a difficult argument to make. See id. By
contrast, Acting Commissioner Michael Friedman has publicly agreed with the stance
taken by the BIO that cloning falls under FDA authority to regulate biologics,
although the agency has "yet to issue a formal policy statement on its justification to
govern cloning experiments." Id.Former FDA lawyer Arthur Levine stated, "'[i]t is
not uncommon, in this kind of sensitive area involving medical ethics, for the FDA to
take a position through various informal statements, drafts, and meetings where they
try to explore what the market will bear ....These are informal ways that FDA tests
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justify FDA authority over human cloning: (1) designation of cloning
materials as "biological products" pursuant to § 351 (a) of the PHSA;"
(2) designation of such products as "drugs" pursuant to § 201(g) of
the FFDCA;27 and (3) regulation of cloning procedures as "medical
devices" under § 201 (h) of the FFDCA.29 Exercise of FDA regulatory
authority over human cloning pursuant to any one of these statutory
provisions would include premarket approval requirements and a
need by the researcher to demonstrate the safety and efficacy of the
cloning procedures.2
Without doubt, any attempts at human cloning would be
the water.'" Id. Historically, biologics consisted of blood products and vaccines, but
today are regulated under guidelines that include products composed of a living
organism such as human cells or tissue that are "substantially altered, through 'more
than minimal manipulation.'" See id. Although Levine suggested that an argument
for FDA authority over cloning could be made, another lawyer with expertise in food
and drug law believed that the biologics provisions were not applicable to cloning.
See id The manipulation of cells might not be considered therapeutic in function
since the intent "is really to create a new human being." Id (internal quotations
omitted); see also FDA Asserts Human Cloning Authority, FAcTS ON FILE WORLD NEWS
DIG.,Jan. 22, 1998, at 29 (reporting that Dr. Friedman stated that cloning required
FDA approval under the FFDCA as a type of cellular genetic therapy).
42 U.S.C. § 262(a) (1994).
21 U.S.C. § 321(g)(1) (1994).
21 U.S.C. § 321(h) (1994); see also Elizabeth C. Price, Does the FDA Have
Authority to Regulate Human Cloning, 11 HARv. J.L. & TECH. 619, 620 (1998); F.D.C.
Reports, 60 "The Pink Sheet" No. 32, Aug. 10, 1998, at 3. The Pink Sheet notes that
a questionnaire prepared by Republican members of the Senate Labor and Human
Resources Committee in August 1998 and presented to FDA Commissioner nominee
Jane Henney specifically asked "which section of the FD&C Act gives FDA authority,
and whether it would apply its drug, device, or biologics rules." Id
29 See 42 U.S.C. § 262 (a) (1) (A) (1998) (requiring biologics
license for biological
products introduced into interstate commerce); 42 U.S.C. § 262 (a) (2) (B) (1998)
(setting forth the requirements of safety, purity, and potency for licensure of
biological products); 21 C.F.R. § 600.3(p) (1997) (defining safety of biological
products as "relative freedom from harmful effect to persons ... when prudently
administered, taking into consideration the character of the product... "); 21 C.F.R.
§ 600.3(r) & (s) (defining purity and potency of biological products, respectively); 21
U.S.C. § 321(p)(1) (1994) (defining the term "new drug" as any drug which is "not
generally recognized, among experts qualified by scientific training and experience
to evaluate the safety and effectiveness of drugs, as safe and effective for use under
the conditions prescribed, recommended, or suggested . . ."); 21 U.S.C. § 355(a)
(1994) (necessitating approval of a new drug application prior to introduction of any
new drug into interstate commerce); 21 U.S.C. § 355(d) (setting forth the grounds
for refusing or approving a new drug application and delineating the safety and
efficacy requirements); 21 U.S.C. § 360(c)(a)(1)(c) (1994) (requiring premarket
approval for class III medical devices to ensure safety and efficacy); see also
Establishment Registration and Listing for Manufacturers of Human Cellular and
Tissue-Based Products, 63 Fed. Reg. 26,744 (1998), 63 Fed. Reg. 68,212 (1998)
(requiring premarket approval for cells and tissues that are processed extensively or
have a system effect).
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deemed experimental by the FDA and would thus require submission
of an IND application by the clinical researcher, as well as
institutional review board (IRB) oversight."0 Given the high failure
rates in sheep-cloning attempts, it is highly unlikely that the FDA
presently would approve any IND application involving human
cloning, and if empowered, would place a clinical hold on any such
attempts."' The real question is whether the FDA has authority to
regulate cloning in the first place. Part I of this Article provides a
brief background of the science of cloning. Part II explores the
ideological differences and ethical arguments inherent in the cloning
debate. Part III outlines the most significant legislative responses to
the human cloning controversy and notes the various levels of
support for FDA authority over cloning by various constituencies.
Finally, Part IV analyzes the legitimacy of FDA authority under the
aforementioned regulatory schemes.
I. THE SCIENCE

The term "cloning" has been used differently in various research
settings."' A strict scientific definition of cloning, however, describes
the process of producing a "precise genetic copy of a molecule, cell,
plant, animal, or human being."3 Cloning technologies are not new
30

See Nightingale, supra note 21 (explaining the FDA's position, as circulated in a

"Dear Colleague" letter, regarding the applicability of the IND application and IRB
processes to human cloning); see also 21 C.F.RL § 312.2(a) (1999) (applying the IND
application process to clinical investigations of new drugs subject to § 505 of the
FFDCA and to the licensing of biological products under the PHSA); 21 C.F.R. §
312.22(a) (1996) (describing general principles of the IND submission); 21 C.F.R. §
312.23(a)(6) (delineating requirements for protocol description, including
investigator qualifications); 21 C.F.R. § 312.32 (listing IND safety report
requirements); 21 C.F.R § 312.62 (detailing investigator record keeping and record
retention requirements); 21 C.F.R. § 312.64 (describing investigator progress, safety,
and final report requirements); 21 C.F.RL § 312.66 (ensuring IRB review); 21 C.F.R. §
312.42 (outlining the "clinical hold" process in situations determined to pose an
"unreasonable and significant risk of illness or injury" to human subjects).
s1 See Seachrist, supra note 17 (postulating the FDA position regarding human
cloning attempts).
32 See NBAC REPORT, supranote 1, at 14.
Id. Henry T. Greely has noted:
The term "clone" dates to the beginning of the twentieth century when
agricultural scientists adapted it from the Greek word "clon," meaning
twig. The term was used to refer to the process of producing new
copies of plants by cuttings rather than by seeds ....
The verb "to clone" has come to refer to the reproduction of a
living organism or some of its parts without the mixing of genetic
information caused by sexual reproduction. "Clones," the noun, are
thus a set of organisms or parts of organisms that are identical
genetically, and, in the case of specialized types of cells, are identical in
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and have been'used extensively in both horticulture and agriculture
to maintain various plant varieties.? For example, regenerating an
entire plant from a small cutting produces a genetically identical copy
of the original plant. Although some animals can, to some extent,
regenerate certain organs, tissues, or limbs, vertebrates have lost the
ability to generate another whole organism in an analogous fashion.?3
Production of genetically identical copies of organisms, however,
does occur naturally in animals and humans in the form of identical
twins. 7 The splitting of an early embryo (typically two to eight-cell
stage) into halves results in genetically identical offspring derived
from a single fertilized egg.8
At the molecular level, cloning of deoxyribonucleic acid (DNA)
fragments containing genes has been ongoing for several decades."'
The process of using bacteria to copy and amplify human DNA
fragments and manufacture proteins coded from these fragments has
been the foundation for recombinant DNA technology.
This
technology has led to the production of commercially available
quantities of valuable medicines to treat human disease.?4
Culturing somatic (i.e., body) cells in a laboratory is another
form of cloning that results in a cell line genetically identical to the
original cell. This cellular cloning technique has been used to test
and produce new medicines.4' In addition, primordial stem-cell
therapy, based on cellular cloning techniques, has the potential to
revolutionize health care.4
Clinical trials are already being
both what genes they have and what genes they are using.
Henry T. Greely, Banning "Human Cloning": A Study in the Difficulties of Defining
Science, 8 S. CAL. INTERDIsc. L.J. 131, 132-33 (1998).
35
36
37
38

See NBAC REPORT, supra note 1, at 14.
See id.
See id.
See id.

See id.

See id.
40 See NBAC REPORT, supra note 1, at 14.
Insulin used in the treatment of
diabetes, erythropoietin used to treat anemia associated with end-stage renal disease,
and tissue plasminogen activator used to dissolve coronary artery clots during the
evolution of a heart attack are examples of clinically useful products of recombinant
DNA technology. See id
4
See id. at 14-15. Cloning of somatic cells in this manner does not involve
the
use of egg or sperm cells, thus it precludes the cloning of an entire organism. See id.
42 See Prepared Testimony of Michael D. West, Ph.D., Founder
and Chairman of Origin
Therapeutics, Inc., South San Francisco, California, on Behalf of the Biotechnology Industry
Organization(BIG) Before the House Committee on Commerce, Subcommittee on Health and
Environment, Subject - Legislative Proposals Regarding Cloning of Human Beings, FED.
NEws SERv., Feb. 12, 1998 (hereinafter West]. Primordial stem cells are different
39
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conducted utilizing nonprimordial stem cells for therapeutic
purposes such as cancer treatment."
Attempts to clone genetically identical animals are typically
blastomere
classified as one of two separate methodologies:
transplantation
nuclear
and
splitting,
embryo
or
separation,
techniques." Blastomere separation involves the splitting of an early
embryo, allowing each split blastomere cell to develop into a separate
These cells, considered totipotent, are capable of
organism."
producing multiple genetically identical organisms when split.4 This
technique exhibits great potential in the area of cattle and livestock
breeding.4 Since 1993, embryo splitting has also been successfully
performed with human embryos."
from other stem cells, which have differentiated into a specific cell line. See idi
Because many tissues in the body do not contain stem cells, any injury to them is
permanent and disabling. See id "By way of contrast a primordial stem cell has the
potential to become literally any cell in the body and therefore it offers a solution to
many untreatable diseases and conditions." Id Primordial stem-cell therapy has the
potential to restore damaged cells in the body, including
cardiac muscle cells to treat heart attack victims and degenerative heart
disease; skin cells to treat burn victims; spinal cord neuron cells for
treatment of spinal cord trauma and paralysis; neural cells for . . .
neurodegenerative diseases; pancreas cells to treat diabetes; blood cells
to treat cancer, anemia, and immunodeficiencies; neural cells to treat
Parkinson's, Huntington's and Amyotrophic Lateral Sclerosis (ALS);
cells for use in genetic therapy to treat 5,000 genetic diseases ... blood
vessel endothelial cells for treating artherosclerosis; liver cells . . .
cartilage cells ... bone cells ... myoblast cells for the treatment of
Muscular Dystrophy; respiratory epithelial cells for the treatment of
Cystic Fibrosis and lung cancer; adrenal cortex cells•., retinal pigment
epithelial cells for age-related macular degeneration ....
Id. Various stem cells differentiate into a variety of cell types and are self-renewing.
See id. Primordial stem cells are undifferentiated stem cells that are able to
differentiate into many different types of cells and may "provide a means of
manufacturing any human cell type in the industrial setting." Id. This technology
may even resolve ethical issues related to the source of material for transplantation.
See id Primordial stem-cell research could possibly result in the development of
"universal donor cells." See id. (internal quotations omitted).
45 See i& For example, hematopoetic stem cells can be isolated
from the blood of
adults or children, cloned by cellular culturing techniques, and used to treat human
disease, such as cancer. See i4.
See NBAC REPORT, supra note 1, at 15.
45See

id.

See id.
47 See id.; see also Gina Kolata, Japanese Scientists Clone a Cow,
Making Eight Copies,
N.Y. TIMs, Dec. 9, 1998, at A8. Kolata observes that "one reason for cloning cattle
would be to reproduce exact copies of animals that are superb producers of meat or
milk." Id. The procedure the Japanese used to clone a cow involved transfer of
somatic cell nuclear material into an enucleated egg. See id
See Gina Kolata, Scientist Clones Human Embryos, and Creates an Ethical Challenge,
4
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Nuclear transplantation cloning is a more sophisticated cloning
method and involves removing the haploid nucleus from an egg cell
and replacing it with the diploid nucleus of a donor somatic cell.49
Early experiments using this technique in frogs, mice, cattle, and
rhesus monkeys were successful when embryonic cells served as the
donor cell.' ° Dolly's birth, which resulted from the use of an adult
cell nucleus donor, was astonishing proof that "cell differentiation
and specialization are reversible" and that a fully differentiated adult
cell nucleus could be reprogrammed to produce an entire, viable
mammal.51
It also seems possible to pair somatic cell nuclear transfer
techniques with primordial stem-cell research to produce

N.Y. TIMES, Oct. 24, 1993, at Al.
4
See NBAC REPORT, supra note 1, at 15. Somatic cells contain a diploid nucleus
that contains two sets of genes, one set contributed by each parent. See id. Germ
cells (i.e., egg or sperm cells) contain haploid nuclei, either maternal or paternal in
gene composition. See id.A fertilized egg then acquires a full diploid complement of
chromosomes with genetic contributions from both parents. See id. By contrast,
nuclear transplantation cloning results in a single genetic parent. See id. "The result
is an animal that is essentially an identical twin of the donor animal, although the
cloned offspring has a small genetic contribution - the mitochondrial genome from the animal providing the enucleated egg cell." Joan Stephenson, Threatened
Bans on Human Cloning Research Could HamperAdvances, 277JAMA 1023, 1023 (1997).
50 See Stephenson, supra note 49, at 1023-25.
51 NBAC REPORT, supra note 1, at 16; see also Stephenson, supra note 49, at 1025.
Recognizing that all somatic cells within a given organism contain the same diploid
DNA composition, Stephenson explains:
[U]ntil Dolly, many researchers had speculated that cloning attempts
using nuclei from nonembryonic cells might be doomed to failure,
because they hypothesized that the developmental pathways from
totipotent embryonic stem cells to differentiated liver, brain, or kidney
cells were strictly 1-way. They believed that chemical and structural
changes in the DNA presumed to take place during differentiation
would prevent differentiated cells from switching on genes silent in
those cells and switching off or muting the genes responsible for a
differentiated cell's distinctive properties.
Id. The Roslin group used a new technique in which the nutrient content of the
culture medium used to support the adult donor cells was reduced in order to
induce the DNA to enter the quiescent GO or G1 stages of the cell cycle. See id This
caused the DNA activity to more resemble that of germ cells. See id. An electric
current was used to fuse the donor nucleus with the enucleated egg, creating a cell
with its DNA apparently reprogrammed by substances in the egg's cytoplasm. See id.
The fused cell behaved like a fertilized egg, started to divide, and then developed
into an embryo that was subsequently implanted into the surrogate mother for
gestation. See id. Apparently, the genome of differentiated cells is "malleable
enough to permit formerly quiescent genes to be switched on and active genes to be
switched off." Id. For a more detailed report on the scientific history leading up to
the successful cloning of Dolly the sheep and various techniques used in somatic cell
nuclear transfer, see NBAC REPORT, supranote 1, at 13-38.
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"customized" stem cells reflecting the DNA of a particular patient.-"
A physician might want to generate primordial stem cells containing
DNA identical to the recipient patient, thereby ensuring that the
"therapy would be compatible with, and not be rejected by, the
person for whom the therapy is created." s To accomplish this,
researchers would use somatic cell nuclear transfer technology to
"reprogram somatic cell nuclei to generate more undifferentiated
primordial stem cells for that patient.""
There are many reasons to permit animal cloning research to
continue.0 Cloning technologies may be used to produce groups of
genetically identical animals for research purposes, thus eliminating
genetic differences that often lead to experimental variation. 6
Cloning research also has the potential to provide a means of
expanding the number of livestock with desirable traits such as
enhanced meat or milk production.5 ' The use of nuclear transfer
technology is also apt to bring about major advances in the
production of transgenic livestock, resulting in a wide array of
medical benefits for humansi 8 The value of molecular and cellular
cloning techniques for the treatment of human disease has already
been discussed. In addition, adult cell cloning techniques ultimately

52 See West, supra note 42. West remarked that the "process of using
the patient's
own cells is similar to current technologies that utilize a patient's own bone marrow,
cleansing it of cancer, irradiating the remaining bone marrow in the patient. . . and
then giving them a bone marrow transplant of their own bone marrow." Id. Some
patients have a compatible sibling to serve as a marrow donor, obviating the need for
this hazardous procedure, and very few have twins available for this purpose. See id.
53 Id.
54

Id.

See NBAC REPORT, supranote 1, at 24.
See id. at 24-25.
57 See id.
at 25.
See West, supra note 42. Examples of the potential usefulness of transgenic
animal initiatives include: (1) Animal models for testing: In order to decrease the
time needed to develop human drug therapies, medicines can be tested on
laboratory animals genetically manipulated to be susceptible to human diseases; (2)
Organ transplantation: To greatly increase the supply of available organs for human
transplantation and to minimize the risk that the genetically altered animal organ
will be rejected by its recipient, human genes can be transferred into animals that are
subsequently cloned for organ donation to human patients; and (3) Production of
medicine in animal milk or eggs: Human genes can be transferred into dairy animal
or commercial poultry cells that are subsequently used to clone animals capable of
producing therapeutic human proteins in their milk or eggs. See id. For example,
the milk of livestock can be modified through the use of nuclear transfer technology
to contain substantial quantities of important therapeutic proteins, such as insulin
for treatment of diabetes or factor VIII for hemophilia. See NBAC REPORT, supra note
1, at 26.
5
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may be helpful in preventing the extinction of endangered species.59
Furthermore, research on nuclear transfer cloning techniques used
to generate targeted gene alterations in laboratory animals has
proven invaluable in studying normal gene function and in
developing accurate models of human genetic disease.&o It is also
anticipated that ongoing animal cloning research will further
scientific knowledge on cell differentiation. 6' Finally, continued
research on nuclear transfer procedures should find significant
6
application in the field of assisted reproduction."
Despite the myriad potential benefits of nuclear transfer cloning
research in animals, this technology is not without risks and safety
concerns, especially when applied to humans. One concern is for the
safety of a surviving clone. Due to the accumulation of genetic
mutations throughout life, the older the organism, the greater the
predisposition to cancer.'
Thus, a donor somatic cell used for
cloning may contain the accumulated mutations acquired during
years of cell division, which may possibly lead to a predisposition for
cancer, premature aging, or immunological disease in the resulting
clone.f4 In addition, the possibility that some instability in genetic
59 See Robert Winston, The Promise of Cloning for Human Medicine:
Not a Moral
Threat but an Exciting Challenge, 314 BRIT. MED. J. 913, 913 (1997). Are the fictions
portrayed in Michael Crichton's Jurassic Park closer to reality than anyone now
realizes? See generally MICHAEL CRICHTON, JURASSIC PARK (1990) (envisioning a grandscale theme park, populated by previously extinct dinosaurs that were brought to life
through advances in cloning technology).
60 See NBAC REPORT, supra note 1, at 26-28.
61

62

See id. at 28-29.
See id. at 31.

See Stephenson, supra note 49, at 1025; see also D.J. Galton et al., Human
Cloning: Safety Is the Issue, NATURE MED.,June 1998, at 664. The authors explain this
enhanced risk of disease with the use of somatic cell nuclear transfer for
reproduction:
In sexual reproduction, the zygote receives a random assortment of
alleles from each parent, and previous somatic mutations of one parent
are paired with alleles of the other, thus diluting the load of somatic
mutations from each parent. In contrast, when a zygote receives its
entire genetic complement from a nucleus derived from an adult
tissue, further accumulation of somatic mutations during development
may lead to increased risks of genetic abnormalities, especially when
previously inactive genes become dce-repressed in differentiating
embryonic tissues. It would be outrageous to handicap a child from
birth with a multitude of somatic mutations from the adult nucleus
used for transfer, particularly as there is no possibility of informed
consent for the experiment.
Id.
rA See supra note 63 and accompanying text (detailing the possible effect of
accumulated genetic mutations in the development of disease in the cloned
63
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imprinting may exist, particularly in cultured cells, could limit the
efficiency of somatic cell nuclear transfer.8 Researchers have learned
"that disturbances in imprinting lead to growth abnormalities in mice
and are associated with cancer and rare genetic conditions in
children."6 6 Other safety concerns would apply to human egg donors,
recipients of cloned embryos for gestation, and the nonsurviving
cloned embryos. The fact that only 1 live birth resulted from 29
implanted embryos, which in themselves resulted from 277 cellular
attempts at cloning, attests to the unresolved safety issues applicable
to human cloning.
In addition to the Roslin Institute, various other institutions have
Researchers at the University of
attempted to clone animals.
Massachusetts cloned two calves from the skin cells of cow fetuses. 8
Reproductive biologist Neal First of the University of Wisconsin, and
offspring); see also NBAC REPORT, supra note 1, at 23 (describing the progressive
shortening of the ends of the chromosomes, the telomeres, and other genetic
changes observed with cellular aging).
See id. Imprinting relates to "the fact that the genes inherited on the
chromosomes from the father.., and those from the mother ...are not equivalent
in their effects on the developing embryo .... [C]ertain genes are expressed only
when inherited from the father or mother." Id
66 Id.
67 See

Wilmut, supra note 6, at 74 (reporting the scientific findings of the Roslin
Institute's sheep-cloning experiments); see also Lori B. Andrews, Human Cloning:
Assessing the Ethical and Legal Quandaries,CHRON.OF HIGHER EDUC., Feb. 13, 1998, at
B4.
Many in vitro fertilization clinics currently utilize a procedure called
"intracytoplasmic sperm injection," in which a single sperm is injected into an egg.
See id.This method could easily be adapted to clone humans. See id. Although
fertility clinics in the United States are free to offer fertility treatments of their own
choosing, they are not required to report when children resulting from reproductive
technologies have birth defects. See id. Several studies have demonstrated that
"children born after intracytoplasmic sperm injection ... were twice as likely to have
major congenital abnormalities as were children conceived naturally." Id. A report
in the January 15, 1998 issue of the Netw EnglandJournal of Medicine also reported a
case in which embryos created through in vitro fertilization and implanted in a
woman's uterus fused, creating a "chimera" possessing both male and female sex
organs at birth. See id. (citing Lisa Strain et al., A True Hermaphrodite Chimera Resulting
from Embryo Amalgamation After In Vitro Fertilization, 338 NEW ENG. J. MED. 166, 166
(1998)).
See Carey Goldberg & Gina Kolata, Scientists Announce Births of Cows Cloned in
New Way, N.Y. TIMEs, Jan. 21, 1998, at A14. Doctors James Robl and Steven Stice
successfully cloned two calves and subsequently announced that they viewed this
achievement as a major step toward commercialization of the technology. See id.
Both scientists work for Advanced Cell Technology, Inc., a biotechnology start-up
company that already has a contract to produce a herd of genetically engineered
cattle that can produce human serum albumin. See id.The company is also working
on cloning pigs and plans to use cloned transgenic cows as donors for neural cells
that can be used to treat human disease. See id.Although researchers do not know
how to reprogram genetic material, an unfertilized egg is capable of this feat. See id
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Tanja Dominko of the Oregon Regional Primate Research Center
inserted DNA from several species into enucleated cow eggs, and the
eggs activated the DNA to produce a clone of the DNA donor.6
University of Hawaii scientists cloned fifty mice from adult cells,
nearly duplicating the process used at the Roslin Institute." Japanese
scientists reported in 1998 that "they . . .cloned eight calves from

cells they gathered from a slaughterhouse, creating eight identical
copies of a single cow." 7 1 Cloning of cows follows the cloning of a

lamb and mice as the third such recorded milestone involving adult
mammals, and the science behind these feats may prove "at least as
efficient as in vitro fertilization. "7 With animal cloning research
advancing at such a rapid pace, the focus on regulation of this
technology is only apt to intensify.
II. ETHICAL CONSIDERATIONS
Apart from the safety concerns, human cloning raises a number
of moral concerns, especially relating to the potential psychological
harm to children. Well-articulated arguments have stressed that the
cloning of humans would be associated with a "diminished sense of
individuality and personal autonomy" and would have a detrimental
effect on the quality of family life and parenting.74 Eugenic concerns
and fears that human cloning would lead to the objectification or
commodification of children are two additional ethical issues that
need to be addressed. 7 Weighing against these arguments are
See Andrews, supra note 67, at B4. This discovery "raises the theoretical
possibility that cow eggs could be used as a universal incubator for any adult
mammal's cell" and that women could then possibly avoid the risks associated with
eggdonation. Id.
7o See Mice Clones Prove 'Dolly' was no Fluke, MED. INDUST. TODAY, July 24, 1998.
Ryuzo Yanagimachi and Teruhiko Wakayama announced that the process
demonstrates that cloning can become routine and could perhaps also be used to
grow vats of skin or other organs for transplantation. See id.; see also Gina Kolata, A
Tale of (Cloned) Mice and Men, INT'L HERALD TRIB.,July 25, 1998, at 4.
71 See Kolata, supranote 47, at A8.
SId.
Dena S. Davis, What's Wrong with Cloning?, 38JuRIMETRlcsJ. 83, 83 (1997).
69

74Id.

See NBAC REPORT, supra note 1, at 69-72. Regarding eugenics concerns, the
NBAC Report goes on to say:
[W]hat is at issue in eugenics is more than an individual act, it is a
collective program. Individual acts may be undertaken for singular
and often unknown or even unknowable reasons, whereas a eugenics
program would propagate dogma about the sorts of people who are
desirable and those who are dispensable. That is a path humanity has
trodden before, to its everlasting shame. And it is a path to whose
return the science of cloning should never be allowed to give even the
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considerations of privacy, personal choice regarding procreation and
child rearing, and the freedom of scientific inquiry.6
Cloning, if available as a means of reproduction, would most
likely be pursued by couples who are unable to conceive a child
because of infertility, or by couples who carry a high risk of
inheritable genetic disease." Cloning under these circumstances is
morally less controversial and less likely to pose significant
psychological harm to the child. 8 This is not to say, however, that
cloning a parent in these situations would be without challenges.
How would a wife, for example, react to a younger "copy" of her
husband?n How would a parent react to living with a clone of himself
slightest support.
Id.at 72.
76 See Harold T. Shapiro, Ethical and Policy Issues of Human Cloning,
SCIENCE, July
11, 1997, at 195. Constitutional principles that conflict with a ban on cloning
include "the right of adults to have children and the right of scientists to investigate
nature." Mark D. Eibert, Clone Wars; Laws on Human Cloning, REASON, June 1998, at
52. The United States Supreme Court has opined "that every American has a
constitutional right to 'bear or beget' children... [including] the right of infertile
people to use sophisticated medical technologies like in vitro fertilization." Id. Once
human cloning is perfected, infertile couples could use any somatic cell to conceive
children, thereby offering many couples the only possible avenue to assert their
constitutional right to procreate. See id. Arguably, cloning bans would have the
practical effect of forced sterilization. See id. Other commentators have asserted
similar positions. See generally Lori B. Andrews, Is There a Right to Clone? Constitutional
Challenges to Bans on Human Cloning, 11 HARV. J.L. & TECH.643 (1998) (providing an
in-depth analysis on the constitutional issues involved with cloning restrictions); Gina
Kolata, Human-Cloning Debate Growing Far Less Shrill Opposition Remains, but Benefits
Are Discussed, DALLAS MORNING NEWS, Dec. 7, 1997, at A10. Kolata notes that "it is an
American tradition to allow people the freedom to reproduce in any way they like."
Id.; see also infra note 149 (discussing judicial decisions addressing the constitutionally
protected right of procreation).
77 See Robertson, supra note 13, at 119. Infertile couples suffering from
gametic
insufficiency might elect to clone one of themselves rather than to rely on an
anonymous donation of sperm, egg, or embryo. See id "(T]here is nothing
inherently wrong in wishing to be biologically related to one's children, even when
this goal cannot be achieved through sexual reproduction." Id. Couples at high risk
of having children with genetic disease
must now choose whether to risk the birth of an affected child, to
undergo prenatal or preimplantation diagnosis and abortion or the
discarding of embryos, to accept gamete donation, to seek adoption, or
to remain childless. If cloning were available, however, some couples.
..might strongly prefer to clone one of themselves or another family
member. Alternatively, if they already had a healthy child, they might
choose to use cloning to create a later-born twin of that child.
Id; see also Kolata, supra note 76, at A1O (quoting Dr. Steen Willadsen, cloning
pioneer and infertility expert from St. Barnabas Hospital, New Jersey, as stating,
"cloning may be bad but telling people how they should reproduce is worse").
78 See Davis, supra note
73, at 85.
See Wilmut, supra note 6, at 74.
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and what would that parent's understanding and expectations of his
cloned offspring be? ° How would a cloned child cope with a full
awareness of his physical future?"1
Other reproductive motives are significantly more controversial.
For example, parents may seek to replace a child who died young,82
or is terminally ill,83 by using cells from the deceased or dying child to
create a new embryo. Psychological problems may later manifest
themselves in the child if the parents' motivations were founded on a
mistaken belief of "the importance of genetics over environment."8
Parental frustrations are likely when the child fails to live up to the
expectations established by the deceased sibling.85 The grieving
parents in these circumstances may not seek a new baby, but rather
the return of the deceased child.
Another motivation for human cloning that is sure to generate
ethical debate is the creation of clones for the purpose of donating
organs or tissues to seriously ill family members. 7 Although there
may be no reason to fear that such clones would be exploited to any
greater degree than when existing offspring donate organs or tissues
to their siblings, a level of discomfort arises when children are
80
81

See id.
See id

See Davis, supra note 73, at 86.
See Kolata, supra note 76, at A10.
Davis, supra note 73, at 86.
85 See id Health care professionals should refuse to
comply with the couple's
wishes in these situations, especially if the couple is able to reproduce in other ways.
See id. But see Kolata, supra note 11, at Al. Kolata acknowledges that in certain
specialized situations, such as when grieving parents wish to reproduce a terminally
ill child, scientists and infertility experts question whether it is worse to clone a
parent or to procure an embryo "made-to-order" with donated sperm or egg, as is
currently an option at fertility clinics. See id. A couple without eggs or sperm might
want to contemplate cloning both wife and husband. See id
86 See Wilmut, supra note 6, at 74. The issue, however, becomes less clear when
the lost child is very young because fewer expectations would be placed on the
cloned replica. See id The difficulty in crafting legislation banning the cloning of
older children and adults while permitting the cloning of infants is self-evident. See
id.
87 See Davis, supra note 73, at 86. The NBAC
Report describes a scenario in which
the clinic is utilized for "spare parts" as follows:
The parents of a terminally ill child are told that only a bone marrow
transplant can save the child's life. With no other donor available, the
parents attempt to clone a human being from the cells of the dying
child. If successful, the new child will be a perfect match for bone
marrow transplant, and can be used as a donor without significant risk
or discomfort. The net result: two healthy children, loved by their
parents, who happen to be identical twins of different ages.
82
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intentionally created for purposes of donation, instead of being a
desired end in and of themselves."
Cloning also has been proposed as a method available to parents
for the selection of particular physical characteristics in an effort to
produce the "child of their dreams." 9 Attempts to clone a film star,
athlete, or scientist, based on parental interests, ignore the fact that
personality is not based solely on genetics.9° Family conflict would
likely arise if the cloned offspring did not live up to the lofty
expectations of the parents. 9' Cloning with these intentions in mind
"violates what philosopherJoel Feinberg calls 'the child's right to an
open future,' because it violates the child's nascent"92autonomy and
narrows the scope of her choices when she grows up.
A further concern expressed when evaluating the ethical
implications of cloning technology is that cloning leads to
commodification

-

"treating persons . ..as ... thing[s] that can be

exchanged, bought, or sold in the marketplace." 93 Parents motivated
to produce a specific child, and no other, may inadvertently impose
this burden on their child, who subsequently is perceived as a
consumer product."
On the other hand, parents who avail
themselves of cloning technology simply because they want a child
who is biologically related to one of them are no more likely to

88 See id. at 86-87.

It may not be ethically problematic if a cloned child is created

partially for the reason of organ or tissue donation because parents elect to bear
children for a variety of reasons, including, for example, to preclude the first born
from being an only child. See id. Eventually, it may be possible to obtain compatible
organs or tissues for transplantation by "cloning the source DNA only to the point at
which stem cells or other material might be obtained for transplantation, thus
avoiding the need to bring a child into the world for the sake of obtaining tissue."
Robertson, supra note 13, at 119.
See Wilmut, supranote 6, at 74.
90 See id.
91 See id. "Every child should be wanted for itself, as an individual." Id. The need
89

to consider the child's interest outweighs the rights of individuals to procreate in
ways that they choose. See id. Wilmut specifically rejects this proposed cloning use.
See id.
Davis, supra note 73, at 87. It is true that parents often try to influence the life

choices of their children; permitting child cloning to achieve these goals, however,
elevates this concern to a new level. See id.The child's opportunity to pursue his
own interests and options may thus be severely limited. See id. at 88.
93Id. (quoting NBAC REPORT, supra note 1, at 73) (internal quotations omitted).
See id.at 88-89. Ethicists have opined that enabling parents to uncover major
genetic disorders prenatally, with the option of abortion, may lead down a slippery
slope to testing for minor physical abnormalities and eventually to allowing parents
to select for specific desired characteristics, such as sex, intelligence, and physical
attributes. See id.at 88.
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commodify their child than are other parents. 95
The widespread availability of human cloning techniques further
expands the reproductive opportunities in nontraditional family
settings. Single parents, or partners in a homosexual relationship,
may elect self-cloning as a means to create an offspring who shares
their genome.9
Public debate on these issues would likely be
significant and extensive.
The legal or social status of a child created through somatic cell
nuclear transfer remains uncertain. Problems that theoretically
could result include familial instability, ambiguity over parental roles,
and self-identity problems for the child." For example, would the
cloned child be considered the sibling or the child of the parents,
and what would the cloned child's status in relation to its
"grandparents" be?"" One can only imagine the added confusion
when attempting to apply the various parentage acts to legal disputes
involving cloned individuals.
Interestingly, religious perspectives regarding the morality of
human cloning are not uniform. 9' Although religious convictions
often provide a significant impetus to limit expansion in human
knowledge, individual theological views on cloning vary.' °° As with
the introduction of any new reproductive technology, the possibility
of human cloning has catapulted the issues of procreative freedom
and the right to life into the public forum.&'
In any event,
95
96
97
9

99

Id.

See id at 89.
See Wilmut, supra note 6, at 74.
See NBAC REPORT, supranote 1, at
66.
See id.
See Shapiro, supra note 76, at 195. Shapiro, citing the NBAC Report,
stated:
Some religious thinkers argue that the use of ... cloning to create a
child would be intrinsically immoral and thus could never be morally
justified. Other religious thinkers contend that human cloning to
create a child could be morally justified under some circumstances but
believe that it should be strictly regulated to prevent abuses.

100 See Eibert, supra note 76, at 52. "Two leading rabbis and a Muslim
scholar who
testified before the National Bioethics Advisory Commission had no objection to the
practice and even advanced religious arguments for cloning." Id By contrast,
politicians have proferred religious arguments against cloning in a bipartisan
fashion, and a theologian representing the National Conference of Catholic Bishops
announced to the President's Commission that "[c]loning exceeds the limits of the
delegated dominions given to the human race." Id.
101 See, e.g., RobertJ. White, Human Cloning Research, 388 NEw ENG. J. MED.
1170,
1170 (1998). White writes that "there are many of us who believe that a human
being is formed at the time of conception... [and] the cloned embryo would be a
human being entitled, in spite of its microscopic size, to the same rights and respect
granted the fully formed child." Id.; see also Maurizio Soldini, Correspondence,
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government restriction or prohibition on human cloning, based
purely on religious grounds, would likely violate the Establishment
Clause.ee
Much concern has been expressed over the potential
psychological risks faced by a cloned child created through somatic
cell nuclear transfer procedures. 3 The "later-born twin" would be
genetically identical to the original somatic cell donor, and therefore
the donor and clone would be far more similar physically than would
a natural parent and child.'
These realities could "undermine
human dignity by threatening the later child's sense of self and sense
of autonomy."' ° Human personality, however, is derived from both
genetic and environmental factors, and thus, analogous to the
situation seen with naturally occurring twins, two clones would be
expected to develop different personalities.'06 The argument may
boil down to the question of whether cloned offspring would be
better off having never been born at all.' 7
Finally, because certain applications of human cloning
technology are likely to be injurious to the cloned offspring, cloning
attempts should proceed only with extreme caution.'" Some cloning
scenarios may be morally and ethically justified, thus counseling
against a total ban on human cloning.'" The temporary ban on
human cloning endeavors recommended by the NBAC appears wellfounded and should provide breathing room for all interested and
qualified parties to debate these issues and to establish reasonable
guidelines for future use of human cloning technology.'
III. LEGISLATIVE RESPONSES TO HUMAN CLONING
Aside from the possibility of FDA authority over human cloning
Human Cloning Research, 388 NEw ENG. J. MED. 1170, 1170 (1998) (asserting that,

from the zygote stage, the embryo is a person, and, thus, experiments on human
embryonic cells is immoral and human cloning should be permanently banned).
102 See Eibert, supra note
76, at 52.
103 SeeAndrews, supra
note 67, at B4.
"04 See Wilmut, supra
note 6, at 74.
105Andrews, supra note 67, at B4.
106 See Wilmut, supra note 6, at 74. Genetics expert Dorothy
Wertz believes "[t]he
notion that cloning is an 'affront to human dignity' and individuality is based on the
erroneous notion that clones would in fact be identical because of identical genes.
'We are not our genes' but subject to many environmental influences." Saltus, supra
note 12, at A6.
107 See Eibert, supra note 76,
at 52.
Ws See Davis, supranote 73, at 89.
109 See
i&
110 See i.
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regulation, there is at present no federal legal mechanism that
prohibits attempts to clone human beings despite widespread
sentiment against the practice.' Although sponsors have introduced
several congressional bills to ban human cloning, no such bill has
been successfully enacted."' Presently, only two states, California and
Michigan, have enacted legislation to ban human cloning."'
Republican bills in the United States Senate would ban the use
of human somatic cell nuclear transfer procedures. 4 Individuals and
entities convicted of violating any provision of the proposed act

I See Caroline Daniel, Conflicting Aims Leave Ban on Human Cloning in Limbo,
WASH. PosT,July 26, 1998, at A8.
112 See id, Although it followed up on the recommendations of the NBAC Report,
President Clinton's proposal, the Cloning Prohibition Act of 1997, found no support
and died. See id Several congressional proposals followed Richard Seed's stunning
announcements of his intent to actually clone humans. See i& Senate bill 1599,
105th Cong. (1998) was initially sponsored by Senator Christopher S. Bond and was
later introduced in its entirety as the Human Cloning Prohibition Act by Majority
Leader Senator Trent Lott. See Greely, supra note 33, at 140 (discussing S. 1601,
105th Cong. (1998)). The Human Cloning Prohibition Act was introduced on
February 3, 1998 by Senators Trent Lott (R-Miss.), Christopher Bond (R-Mo.), and
Bill Frist (R-Tenn.). See id. This bill, which was supported by both the Christian
Coalition and the National Right to Life Committee, would have banned both
embryo and adult cloning. See id However, bypassing the normal committee
proceedings as an emergency measure, the bill failed, receiving only 42 of the
required 60 votes to pass. See id This was due in large part to lobbying by patient
advocacy groups and the scientific community. See id Senators Dianne Feinstein (DCalif.) and Edward M. Kennedy (D-Mass.) introduced rival bills that would prohibit
human cloning but allow research on the cloning of human embryos. See id (citing
S. 1602, 105th Cong. (1998) and S. 1611, 105th Cong. (1998)). No further action
was taken on these bills after its referral to the Senate Labor and Human Resources
Committee. See id. Although more acceptable to the scientific community, the
Democratic bills met strong resistance from the right-to-life groups because the bills
would prohibit any cloned embryos from being implanted, thereby necessitating
their destruction. See Price, supra note 28, at 627. Vernon Ehlers (R-Mich.) is the
only member of the House of Representatives to introduce anti-cloning bills. See Lisa
Seachrist, Armey Wants CloningBill on Floor by Memorial Day, BIowoRLD TODAY, Apr. 29,
1998. These Democratic House bills, H.R. 922, 105th Cong. (1997) and H.R. 923,
105th Cong. (1997), would prohibit federal funding for human embryo cloning
research and human cloning. See id Representative Ehler's embryo cloning bills
subsequently stalled in the House Commerce Committee. See Daniel, supra note 111,
at A8.
113 See Saltus, supra note
12, at A6.
4 S. 1601, 105th Cong., § 301(d) (1998). A human somatic cell nuclear
transfer
is defined as "taking the nuclear material of a human somatic cell and incorporating
it into an oocyte from which the nucleus has been removed or rendered inert and
producing an embryo (including a preimplantation embryo)."
Id. The bill
specifically states, "It shall be unlawful for any person or entity, public or private, in
or affecting interstate commerce, to use human somatic cell nuclear transfer
technology." Id. § 301(a).
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would be subject to both civil and criminal penalties." 5 The blanket
ban on somatic cell nuclear transfer for any purpose that these bills
would impose ventures beyond the NBAC Report's recommendation
to prohibit use of the procedure only for creating a human being. 6
The act would effectively eliminate all research involving human
cloning, including potential beneficial applications,"' such as stemcell therapies."8
See id § 301 (c). Penalties are delineated in the act as follows:
(1) In General -Any person or entity who is convicted of violating any
provision of this section shall be fined according to the provisions of
this title or sentenced to up to 10 years in prison, or both.
(2) Civil Penalty - Any person or entity who is convicted of violating
any provision of this section shall be subject to, in the case of a
violation that involves the derivation of a pecuniary gain, a civil penalty
of not more than an amount equal to the amount of the gross gain
multiplied by 2.
Id The bill could impose a ten-year prison sentence on anyone using this technology
to produce an embryo, even if limited to the laboratory. See Eibert, supra note 76, at
52.
116
See Silberner, supra note 10, at 5.
17
See Eibert, supra note 76, at 52.
118 See West, supra notes 42, 43 and accompanying text (discussing how stem-cell
1

therapy applications could possibly revolutionize health care). It is clear that the
Republican bills would criminalize "customized" stem-cell treatments and may very
well also outlaw some noncustomized stem-cell research. See id. West testified: "[I]t
would be tragic to ban research which is just beginning and holds such promise to
relieve human suffering .... [W]e have every reason to believe that the research will
provide novel and effective treatments for diseases where there is no current therapy
available or current therapies are ineffective." Id. The bills prohibit research if it
could possibly be related to creating a human by cloning, even if the research is not
conducted for that purpose. See id. Greely notes that "an early embryonic cell might
have daughter cells some of which would become germ cells and other somatic
cells." Greely, supra note 33, at 140. Because the Bond/Lott bills do not define the
term "somatic cell," and it is not clear at what stage in germ cell development these
embryonic cells should be considered germ cells instead of somatic cells, the
legislative prohibitions could be circumvented if these diploid embryonic cells are
considered germ cells instead of somatic cells. See id. Alternatively, the ban may be
applied to cases in which the cell nucleus used in primordial stem-cell research is the
combination of the DNA of an egg and a sperm. See West, supra note 42. In this case,
obviously not cloning, the transferred DNA is not identical to that of an existing
human being (diploid somatic cells); the bill could then be interpreted to prohibit
noncustomized primordial stem-cell research as well. See id For the first time in our
history, legislation proposes to ban technology, rather than outcome. See id.
Considering the criminal penalties for violations, the ambiguities in the bill may
indeed have a chilling effect on primordial stem-cell research. See id.; see also 144
CONG. REc. S425 (daily ed. Feb. 5, 1998) (statement of the BIO). The BIO stated
that "the current bill introduced by Senator Bond would, because it goes well beyond
the issue of human cloning, imperil promising biomedical research, including
research to generate stem cells." Id. Despite the potential chilling effect on
biomedical research, right-to-life groups support the bills as written, believing that
the cited technology creates an embryo that is entitled to life. See Price, supra note
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The scientific community overwhelmingly believes that any
legislative action should be limited to the cloning of human beings,
should not include language that impedes important ongoing or
potential new research, and should clearly recognize the distinction
between the cloning of an entire human being and the healing
potential that is derived from biomedical research." 9 Scientific
organizations generally do not support the cloning of human beings,
but do oppose overly broad legislation that goes beyond this narrow
issue and threatens biomedical research that is vital to the discovery
of cures for deadly and debilitating diseases.'" Pro-life groups, on the
other hand, support legislation such as that presented by Republicans
in Senate Bill 1601 because these groups believe that human life
begins with a fertilized egg, and that any cloning research resulting in
a fertilized egg should be banned, regardless of any later intent to
implant the egg and to carry a child to term.'2
Democratic Senators Diane Feinstein of California and Edward
Kennedy of Massachusetts have since proposed legislative alternatives
to the Republican initiatives.'22 These Democratic bills would make it
unlawful for any entity to "implant the product of somatic cell

28, at 625-26.
119 See Wes4 supra note 42 (citing support for the BIO's
position from more than
50 scientific, medical, and patient advocacy groups, as well as from 27 Nobel prizewinning researchers).
120 See id.; see also 144 CONG. REC. S427 (daily ed. Feb.
5, 1998) (statement of the
American Society for Reproductive Medicine (ASRM) offered into record by Senator
Feinstein). The "ASRM is very concerned that in the rush to make human cloning
illegal, Congress will inadvertently outlaw very serious and promising medical
research that may uncover cures to some of the most deadly diseases." Id.
1
See Jennifer Cannon & Michelle Haas, The Human Cloning ProhibitionAct: Did
Congress Go Too Far?, 35 HARv. J. ON LEGIS. 637, 642 (1998). By contrast, opponents
of the Republican bill believe that life does not begin until after the fertilized egg is
implanted in a viable uterus, and thus would permit research that generates fertilized
eggs so long as they are not implanted. See id; see also Senate Vote Fails to Move Cloning
Ban Through Congress, MED. INDUS. TODAY, Feb. 12, 1998 (quoting Boston University
Bioethicist George Annas as stating, "Anything related to embryos or abortions is a
big problem for Congress"). Congress may also be deadlocked on the issue of
cloning legislation "until Congress or the Court decides when life actually begins."
Id.
1
See S. 1602; S.1611; see also Eibert, supra note 76, at 52. S. 1602 would ban
human cloning for 10 years but allow limited laboratory experiments in this area so
long as any resulting human embryos are destroyed early in development, not
implanted in utero, and not allowed to be born. See id.A one-million dollar fine
would be imposed for violations, along with confiscation of all real and personal
property connected with the research. See iii These civil penalties would apply to
prospective parents accessing this technology to procreate, as well as to the
researchers involved. See i&
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nuclear transfer into a woman's uterus."'" This approach focuses on
the banning of cloning technology for the purpose of cloning a
human being, but allows the technology to be used for biomedical
research.2 4 In fact, the proposals contain an express biomedical
research "savings clause" that allows the use of somatic cell nuclear
transfer techniques to clone DNA, molecules, cells, and tissues.Y"
The Democratic alternatives also contain a ten-year sunset provision
requiring a reevaluation of the legislation and a subsequent
recommendation of the NBAC concerning the advisability of a
2 6 Although heavy civil fines would be imposed
continued ban.Y
for
violations of the Democratic legislation, unlike the Republican
i2 West, supra note 42 (discussing S. 1602); The Prohibition of Cloning of Human
Beings Act states, in pertinent part:
(a) Definitions: ... somatic cell nuclear transfer - the term "somatic
cell nuclear transfer" means transferring the nucleus of a somatic cell
of an existing or deceased human child or adult into an oocyte from
which the nucleus or all chromosomes have been or will be removed or
rendered inert.
(b) Prohibitions: It shall be unlawful for any person or other legal
entity, public or private . . . to implant or attempt to implant the
product of somatic cell nuclear transfer into a woman's uterus....
S. 1611. The bill defines the term "somatic cell" as a mature diploid cell. See Greely,
supra note 33, at 141 (citing S. 1602 at 498(c) (a) (4) (1998)). Greely also discusses
the theoretical loopholes emanating from the bill's reference to the terms "somatic
cell," "mature," and "diploid," and in particular, the confusion possibly created when
various congenital chromosomal aberrations are present.
See id. at 141-42.
Interestingly, human somatic cell nuclear transfer procedures using fetal or
embryonic donors are not addressed in the proposed bill. See id. at 144-45. The
Feinstein bill, supported by the ASRM, thus allows the continuation of some human
cloning by infertility specialists, who see value in the transfer of an embryo nucleus to
an enucleated egg with cytoplasm more capable of sustaining healthy embryonic
development. See id.at 145. Other reproductive specialists use embryo splitting, a
cloning procedure, to increase the number of embryos available for implantation.
See id Also, should science progress to the point of developing artificial wombs, the
bill might then be circumvented because implantation would not be "into a woman's
uterus." See Price, supra note 28, at 633. Japanese scientists have been able to
maintain a viable extrauterine goat fetus for up to three weeks in an "extrauterine
fetal incubation device." See id. (discussing Artificial Womb Can Sustain Goat Fetus for
up to 3 Weeks, Cm. TRIB., July 20, 1997, at C8 and Perri Klass, The Artificial Womb Is
Born, N.Y. TIMEs, Sept. 29, 1996, at 117).
24 See West supranote 42.
125See id. S. 1611 provides, in relevant
part:
(c) Protected Research and Practices: Nothing in this section shall be
construed to restrict areas of biomedical and agricultural research or
practices not expressly prohibited in this section, including research or
practices that involve the use of: (1) somatic cell nuclear transfer or
other cloning technologies to clone molecules, DNA, cells, and tissues;
(2) mitochondrial, cytoplasmic, or gene therapy ....
S.1611.
12 See id. § 498C(d).
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proposals, there would be no criminal penalties.2 7 In addition, the
Democratic bills include a clause, supported by the scientific
28
community, that calls for preemption of inconsistent state laws.
The Feinstein-Kennedy proposal may be acceptable to the
scientific community because it does not create a chilling effect on
crucial biomedical research and because it does not ban the use of
somatic cell nuclear transfer technology that falls short of uterine
implantation. '"
However, the bill will not satisfy the pro-life
constituency, which favors the Republican legislative versions,
because the bill does not protect embryos as human life." °
On March 5, 1997, Republican Representative Vernon Ehlers
introduced two bills in the United States House of Representatives,
which provide that no federal funds may be used to conduct or to
support any "research that involves the use of a human somatic cell
for the process of producing a human clone." 3' These proposals
would also permanently outlaw cloning for the purposes of
reproduction as well as any biomedical research leading to this
goal. 3 2 Somatic cell nuclear transfer techniques would be banned
even if these procedures are required for the generation of
primordial stem cells used to treat human disease, notwithstanding
the fact that there may be no intent to generate a human embryo for
uterine implantation and gestation.!
Although Ehler's bills would
outlaw "customized" stem-cell research that utilizes somatic cell
1

See id. § 498C(e).

The bill specifically states that "[a]ny person who

intentionally violates the provisions of subsection (b) shall be fined the greater of
$1,000,000 or 3 times the gross pecuniary gain or loss resulting from the violation."
Id.
12
See Wes4 supra note 42. The NBAC supported state-law preemption
to ensure
comprehensive coverage of the issue, clarity, and interstate uniformity. See id. Welldrafted federal legislation would displace ongoing, variable, and sometimes
ambiguous or poorly drafted state legislative efforts that may have an adverse impact
on important biomedical research. See id.
19 See Cannon & Haas, supra note 121, at 645;
see also Price, supra note 28, at 627
(noting the opposition to the Democratic bills by the pro-life community, which has
referred to the bills as "clone and kill" bills).
130 See Cannon & Haas, supra
note 121, at 645.
1
NBAC REPORT, supra note 1, at F-24 (citing H.R. 922 and H.R. 923). As initially
introduced, H.R. 923 carried a $5,000 civil penalty for violations of the Act.
Considering the total research cost and financial incentives associated with successful
cloning endeavors, however, these bills may provide little deterrence for such activity.
See id
1
See Meredith Wadman, Republicans Seek to Widen Cloning Ban, NATURE, July
1998, at 6; see also West, supra note 42. Representative Ehler's bill, H.R. 922, would
make the creation of "a zygote through the use of... somatic cell nuclear transfer" a
crime carrying a ten-year prison sentence. Id.
133 See West supra
note 42.
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nuclear transfer technology, the bills would not ban stem-cell
research that is not customized.
On the state level, California enacted the California Cloning Act,
effective January 1, 1998, thus becoming the first state to outlaw
Because the California legislation broadly describes
cloning.' 5
cloning "as creating children by the transfer of nuclei from any type
of cell to enucleated eggs," the legislation would also ban innovative
The
new infertility treatments that are unrelated to cloning.
California statute initially limits the ban on human cloning to five
years.13 Although dozens of other state legislatures have introduced
their own versions of anti-cloning bills, Michigan is the only state thus
far to follow California's lead by enacting such legislation.'38
The current federal legislative stalemate over human cloning
prohibitions exemplifies the virtually impossible task of devising
statutory language acceptable to both the scientific community and

See id West specifically states:
The Ehlers/Science Committee bill does clearly imply that the DNA
used in the somatic cell nuclear transfer be identical to that of an
existing or previously existing human being, so the only type of
primordial stem cell research funding it seeks to ban would be that
which seeks to create "customized" primordial stem cells.
Id.; see also supra notes 52-54 and accompanying text (discussing application of
"customized" primordial stem-cell technology).
1s5 See Eibert, supra note 76, at
52.
i3 Id These new infertility procedures transfer nuclei from older, dysfunctional
eggs to younger and healthier enucleated eggs. See id.These eggs are then fertilized
with the husband's sperm, ultimately resulting in a child with genetic contributions
See id.
By contrast, cloning uses donor nuclei from
from both parents.
differentiated, diploid, adult cells. See id.
1s7 See Daniel, supranote 111, at A8. Recent technological advances may make
the
California bill obsolete. See id. Because the bill prohibits transferring a human
donor nucleus into an enucleated human egg cell, the use of enucleated cow egg
cells as incubators for human somatic cell nuclei would not be forbidden under
California law. See id; see also Andrews, supra note 67, at B4 and accompanying text
(discussing cloning research using enucleated cow eggs as a "universal incubator" for
the nuclei of other mammals). For a more detailed analysis of the California
Cloning Act, see generally Abel, supra note 4.
138 See Saltus, supra note 12, at A6. The Michigan ban encompasses
the idea of a
person grown from a single somatic cell when the new individual is genetically
identical to its parent. See Greely, supra note 33, at 139. Language in the NewJersey.
proposed legislation bans human cloning, which is defined as "the replication of a
human individual by cultivating a cell with genetic material through the egg, embryo,
fetal and newborn stages into a new human individual." A.B. 329, 208th Leg., Reg.
Sess. (NJ. 1998); see also Greely, supra note 33, at 142-43 (discussing the inherent
ambiguities created in the NewJersey bill through use of the terms "cultivating" and
"replication of a human individual," and demonstrating how the language could
apply to the traditional method of human reproduction).
134

SETONHALL LAWREVIEW

[Vol. 30:464

the pro-life constituency. 3 The biotechnology industry, believing
that the FDA has clear authority over human cloning attempts,
asserts that there is no need to enact legislation in this area.'6 On the
other hand, right-to-life organizations would likely prefer the issue to
be debated publicly and resolved through the political process, which
may allow these organizations to wield more influence.'
In February 1998, the FDA, based on safety and efficacy
concerns, announced that it had authority to regulate human cloning
under its biologics regulations, which deal primarily with human
gene therapy and techniques that involve the "material manipulation
of human cells that are then reinserted for medical purposes.""
These regulations and their commentary do not discuss human
reproduction, and the FDA had not previously claimed authority over
other human reproductive technologies.'4 On October 26, 1998, in a
"Dear Colleague" letter issued by Associate Commissioner Stuart L.
Nightingale, M.D., the FDA reaffirmed its authority under the PHSA
and FFDCA to regulate clinical cloning research for the creation of
human beings.'" According to Nightingale, any such attempts at
human cloning would require submission of an IND application and
IRB oversight.'6 Support for FDA regulatory authority over human
139
140

See Price, supra note 28, at 627.
See West; supra note 42.

141

See Price, supra note 28, at 628.

1

Greely, supra note 33, at 151. Following both Richard Seed's daring assertions

of his ability and intention to clone humans and DHHS Secretary Shalala's public
response, the BIO sent Secretary Shalala a letter opining that the FDA had authority
to regulate human cloning as a biological product. See Price, supra note 28, at 624.
Four days after receiving the BIO's correspondence, acting FDA Commissioner
Friedman announced the FDA's agreement with the BIO's position. See id at 625.
Although the FDA did not issue a formal statement on how it would regulate,
Freidman stated that human cloning was a "kind of cellular genetic therapy"
requiring FDA approval under the FFDCA. FDA Asserts Human Cloning Authority,
supra note 25, at 29A2.
See Greely, supranote 33, at 151.
44 See Nightingale,
supra note 21.
4
See id In general, the medical and scientific communities support FDA
jurisdiction over human cloning. See Stolberg, supra note 25, at A14. The BIO and
the Pharmaceutical Research and Manufacturers Association of America believe that
the FDA, rather than Congress, is the proper forum for controlling human cloning
and that the FDA has the scientific expertise to assess the procedure. See id.; see also
Janet Firshein, US. Medical Institutions Seek Voluntary Ban on Human Cloning, LANCET,
Feb. 14, 1998, at 508 (opposing legislative attempts to ban human cloning, the
Association of American Medical Colleges supported FDA regulation of human
cloning); Senate Vote Fails to Move Cloning Ban Through Congress, MED. INDUS. TODAY,
Feb. 12, 1998 (noting the American Society of Reproductive Medicine position,
which supports FDA assertion of jurisdiction over cloning); 144 CoNG. REC. S. 606
(daily ed. Feb. 11, 1998) (statement of Senator Durbin espousing caution on
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cloning is less certain outside of the scientific community." 6 Serious
the
questions remain regarding whether the FDA does indeed possess
14 7
cloning.
human
of
practice
the
regulate
to
jurisdiction
requisite
IV. BASIS FOR FDA AUTHORITY TO REGULATE HUMAN CLONING
TECHNOLOGY

A. Commerce ClauseAnalysis
The FDA's assertion of jurisdiction over human cloning is sure
to elicit various constitutional challenges, such as the violation of the
8
and the
freedom of scientific inquiry under the First Amendment
proceeding with legislative initiatives to ban cloning because the FDA asserted
jurisdiction in this area). But see NationalBioethics Advisoy Commission Members Suggest
Regulation of Cloning Research Through Standing Body, Structure Could Be Modeled on
NIH's RAC, HEALTH NEWS DAILY, Mar. 18, 1997, at 5 (citing benefits of an FDA-like
regulatory structure, similar to the NIH's Recombinant DNA Advisory Committee, to
oversee research involving human cloning experiments).
146 See Price, supra note 28, at 628. Right-to-life groups have been silent since
the
FDA's declaration of cloning jurisdiction. See id; see also Armey Rejects FDA Regulation
<http:
7, 2000)
(visited Jan.
20, 1998)
of Human Cloning (Jan.
(homepage of the office
//freedom.house.gov/library/technology/pr980120.asp>
of the House majority leader). In response to the FDA's assertion of authority over
cloning, House Majority Leader Dick Armey responded: "human cloning cannot be
equated to manufacturing drugs. Human embryos, however they are created, are
human beings. To assert that we need only regulate the practice of human cloning
as if it is a drug, and not a process of creating life, is morally obtuse." Id.; see also 144
CONG. REc. S432 (daily ed. Feb. 5, 1998) (statement of Senator Gregg opposing
agency regulation of cloning, including the FDA, because of the cultural and
scientific importance of this issue).
147 See Caroline Daniel, The Law's Lagging Behind Cloning, Research is Full Speed
Ahead, but Bills to Curb It Languish, NEWSDAY (New York), Aug. 4, 1998, at C3 (noting
that the FDA has not invoked regulatory authority over other novel fertility
treatments). Daniel also quotes University of Virginia Law School professor Richard
Merrill as stating that "[t]he FDA is not supposed to regulate the practice of
medicine." Id. Considering that the FDA does not regulate in vitro fertilization and
other more aggressive fertility procedures (all of which involve manipulation of
cells), the FDA may have difficulty justifying its assertion of authority over cloning
technologies as involving more than minimal manipulation of cells. See id.; see also
F.D.C. Reports, 60 "The Pink Sheet" No. 32, Aug. 10, 1998 at 3 (referencing an
inquiry put to FDA Commissioner nominee Henney asking which section of the
FFDCA conveys authority on the FDA to regulate cloning and whether drug, device,
or biologics rules would apply).
148 See NBAC REPORT, supra note 1, at F-6-7. "If the First Amendment [right to
free speech] protects a marketplace of ideas, it seems likely that it would protect the
generation of information that would be included in that marketplace." Id at F-7.
At least one federal district court, in dicta, has suggested that "scholars have a
'right... to do research and advance the state of man's knowledge.'" Id. (discussing
Henley v. Wise, 303 F. Supp. 62 (N.D. Ind. 1969)). By contrast, other federal courts
have not recognized a First Amendment right of scientific inquiry. See id. (discussing
Margaret S. v. Edwards, 488 F. Supp. 181 (E.D. La. 1990); Margaret S. v. Treen, 597
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violation of a couple's right of privacy or liberty interest in making
procreative decisions.1 4 A further constitutional challenge to FDA
authority over cloning might be based on a lack of authority under
the Commerce Clause. 50
The Commerce Clause of the United States Constitution
empowers Congress "to regulate Commerce with foreign Nations,
and among the several States, and with the Indian Tribes." 5 ' The
F. Supp. 636 (E.D. La. 1984), aff'd sub nom., Margaret S. v. Edwards 794 F.2d 994 (5th
Cir. 1986); Wynn v. Scott, 449 F. Supp. 1302 (1978), afl'd sub nom., Wynn v. Carey,
599 F.2d 193 (7th Cir. 1979)). Although the Supreme Court has not decided this
issue, there is general consensus that the research methods could be regulated for
reasons of public health and safety. See id; see also Andrews, supra note 76, at 661-64
(concluding that the freedom of scientific inquiry is not an absolute right and that
the government could regulate cloning experimentation so long as the regulation
was rational).
149 See NBAC REPORT, supra note 1, at F-6-7.
The right to decide whether to bear
children is a constitutionally protected privacy right and liberty interest that insulates
procreative choices from unnecessary governmental intrusion. See id. (discussing
Planned Parenthood v. Casey, 505 U.S. 833 (1992); Eisenstadt v. Baird, 405 U.S. 438
(1972); Griswold v. Connecticut, 381 U.S. 379 (1965)).
The right to make
reproductive decisions includes the right to use reproductive technologies, such as in
vitro fertilization and embryo donation. See id. (discussing Lifchez v. Hartigan, 735 F.
Supp. 1361 (N.D. I11.(1990), affd sub nom., Scholberg v. Lifchez, 914 F.2d 260 (7th
Cir. 1990)). Whether these constitutional protections would extend to human
cloning attempts remains open to debate. See id. Research involving the cloning of
cells and tissues not intended to create a child would not invoke these constitutional
rights of privacy and liberty, and regulation of this research would be permissible as
long as the government articulated a rational basis for the restrictions. See id. Even if
constitutionally protected as a reproductive decision, attempts to clone a human
being could still be regulated if the government asserts a compelling state interest
and the regulation is narrowly tailored to further that interest. See id. at F-6.
Considering the current state of technology, the unresolved ethical issues, and the
potential physical as well as psychological harm to a child produced by cloning, the
state should be able to meet this burden to ban the procedure. See id.; see also
Andrews, supra note 76, at 664-69 (providing an in-depth analysis of whether a
cloning ban would infringe on the constitutional right to make procreative
decisions). For further analysis of whether a fundamental right to use cloning
technologies exists, see generally Lawrence Wu, Family Planning Through Human
Cloning: Is There a FundamentalRight?, 98 COLUM. L. REv. 1461 (1998) (arguing that
married couples have a fundamental right to procreate using cloning technology).
Cloning an entire human being whose genetic make up is known in advance may
also constitute a form of "genetic bondage" that violates the Thirteenth
Amendment's slavery prohibition. See Andrews, supra note 76, at 668. Cloning of
individuals for the purpose of procuring organs or tissues for transplantation may
also run afoul of the Thirteenth Amendment prohibition of involuntary servitude.
See id. A more detailed analysis of these challenges, however, is beyond the scope of
this Article.
IN See NBAC REPORT, supra note 1, at F-5.
1
U.S. CONSr. art. I, § 8, cl. 3. Pursuant to the commerce power, Congress is
permitted
(1) to regulate the use of the channels of interstate commerce, (2) to
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FFDCA derives its authority from the Commerce Clause, and courts
have subsequently sustained this exercise of constitutional power.'52
Generally, all doubts regarding Commerce Clause powers are
When regulating
resolved in favor of constitutional validity.'
medical or scientific activities, Congress typically and expressly
articulates this jurisdictional element within a statutory provision that
states that the act at issue applies only to activities involving interstate
Human cloning clinics may well assert that their
commerce.15
activities are conducted entirely intrastate and are therefore beyond
the reach of FDA jurisdiction.5' Congressional power over interstate
commerce, however, is not limited to the "regulation of commerce
among the states," but instead extends to those intrastate activities
"which so affect interstate commerce . . .as to make regulation of

them appropriate . . . [for] the exercise of the granted power of
Congress to regulate interstate commerce. " 1
regulate and protect the instrumentalities of interstate commerce, or
persons and things in interstate commerce, even though the threat
may come only from intrastate activities, and (3) to regulate those
activities having a substantial relation to interstate commerce.
Anny Huang, FDA Regulation of Genetic Testing: Institutional Reluctance and Public
Guardianship,53 FoOD DRUG L.J. 555, 575 (1998) (citing United States v. Lopez, 514
U.S. 599, 558 (1995)).
152 See Huang, supra note 151, at 575 n.142 (citing United
States v. Sullivan, 322
(8th
Cir.
1969); Dean Rubber
412
F.2d
452
v.
Funk,
United
States
689
(1998);
U.S.
Mfg; Co. v. United States, 356 F.2d 161 (8th Cir. 1966)).
See United States ex rel. Attorney General v. Delaware & Hudson Co., 213 U.S.
(construing federal statutes to avoid conclusion of
366, 408 (1909)
unconstitutionality).
5
See Andrews, supranote 76, at 670.
m See id.; see also Abbot v. Bragdon, 912 F. Supp. 580 (D. Me. 1995), aff'd, 107 F.3d
934 (1st Cir. 1997).
15
Andrews, supra note 76, at 670 (citing United States v. Darby, 312 U.S. 100, 118
(1941)); see also Lopez, 514 U.S. at 558 (recognizing congressional authority to
"regulate those activities having a substantial relation to interstate commerce"). The
"substantial relation" interpretation is probably the best basis for regulating cloning.
Cf Huang, supra note 151, at 575 (supporting this same proposition as it relates to
genetic testing). Supreme Court precedent both supports and contravenes this
position. Compare Wickard v. Filburn, 317 U.S. 111 (1942) (holding that the home
consumption of wheat substantially affected the interstate economics of the wheat
industry) with Lopez, 514 U.S. 549 (rejecting the claim that carrying firearms in school
zones substantially affects interstate commerce and recognizing for the first time in
60 years that there are limits to Congress's power under the Commerce Clause). The
facts of Lopez are distinguishable from the cloning scenario. See NBAC REPORT, supra
note 1, at F-5. In Lopez, the congressional ban on the bearing of firearms within 1000
yards of a school was found not to be a proper exercise of commerce power because
the activity "did not affect interstate commerce, interfered with a traditional state
activity (education), and had already been addressed by state laws in most states." Id
In any cloning effort, equipment, supplies, personnel, patients, and funds are all
likely to move in interstate commerce. See id. The statute and legislative history at
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The federal government's authority to regulate interstate
commerce has already been confirmed in cases in which medicine,
supplies, surgical instruments, or customers move in interstate
commerce."' Cloning facilities will likely acquire similar types of
medical products from other states and will certainly attract patients
from across state lines.'s" Even if the purchase of supplies and
equipment from out-of-state vendors, the reimbursement for services
from out-of-state sources, and the participation of providers in out-ofstate conferences do not individually affect interstate commerce to a
substantial degree, these commercial activities, when viewed in the
aggregate, would affect interstate commerce to the requisite level,
thus conferring congressional authority under the Commerce
Clause.' 59
Health-care providers, including potential cloners, are subject to
the commerce power entrusted to the federal legislature.'M Congress
can ultimately choose to exert direct control over or impose policy
conditions upon health-care provider activity, 16 1 to ban the activity
issue in Lopez also failed to address the Commerce Clause concerns, an oversight not
evident in the FFDCA. See id.; see generaly United States v. Calise, 217 F. Supp. 705
(S.D.N.Y. 1962) (finding that application of the mislabeling provisions of 42 U.S.C. §
262(b) are not restricted exclusively to products moving in interstate commerce);
United States v. Sullivan, 332 U.S. 689 (1948) (holding that the language of § 301(k)
of the FFDCA extended statutory coverage regarding adulteration and misbranding
of articles that passed through interstate commerce to the moment that the articles
were received by the ultimate consumer even though "such article is held for sale
after shipment in interstate commerce").
157 See generally Daniel v. Paul, 395 U.S. 298 (1969)
(finding that a snack bar that
served food to interstate travelers was subject to regulation under the Commerce
Clause); Heart of Atlanta Motel, Inc. v. United States, 379 U.S. 241 (1964) (finding
that a hotel that served interstate travelers was subject to regulation under the
Commerce Clause). If cloning clinics treat out-of-state patients, regulation might
also be sustained under the second prong of Commerce Clause jurisprudence, which
is intended "to protect ... persons . . . in interstate commerce, even though the
threat may come only from intrastate activities." Lopez, 514 U.S. at 558. Another
federal court, also utilizing a Commerce Clause analysis, has affirmed the
constitutionality of the Freedom of Access to Clinic Entrances Act, 18 U.S.C. § 248
(1994), concluding that the rendering of reproductive health services substantially
affects interstate commerce. See United States v. Wilson, 73 F.3d 675, 681-93 (7th Cir.
1995).
158 See Andrews, supra note 76, at 673-74.
Because there are only an estimated 10
laboratories in the world with the ability to replicate Roslin's sheep-cloning success, it
is obvious that human cloning would entail interstate travel. See id. Cloning
providers surely would travel interstate to share research findings and to attend
educational seminars, and any cloned human beings would enjoy the right to
interstate travel. See id.at 674.
15
160

161

See it.
at 672-73.
See i&at 673.
See id.
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completely, 62 or to delegate regulatory authority to a federal agency
under a relevant enabling statute. In any event, the scope of the
Commerce Clause is unlikely to prevent Congress from delegating to
the FDA, or other regulatory agencies, the authority to regulate
cloning. The more important question will likely be one of statutory
interpretation.
B. FDA Regulation of Cloningas BiologicalProducts
Perhaps the strongest argument supporting FDA authority to
regulate human cloning is that cloning may be regulated as a
biological product introduced into interstate commerce.63
"Biological product" is defined under this act as "a virus, therapeutic
serum, toxin, antitoxin, vaccine, blood, blood component or
derivative,
allergenic product, or analogous product, or
arsphenamine or derivative of arsphenamine (or any other trivalent
organic arsenic compound), applicable to the prevention, treatment,
or cure of a disease or condition of human beings."'" Thus, in order
16 See NBAC REPORT, supra note 1, at F-5 (discussing Champion v. Marshal, 188

U.S. 321 (1903)).
163 See 42 U.S.C. § 262 (1994). The FDA has already announced that manipulated
cells and nucleic acids are biological products, that it can regulate cloning as a
biological product, and that the technology can be regulated under the agency's
tissue-products policy, which requires biological license approval for tissues
undergoing significant manipulation. See F.D.C. Reports, 24 "The Gray Sheet" No. 3,
Jan. 19, 1998; see also Seachrist, supra note 17 (citing an FDA source as stating that the
agency is prepared to use the tissue and biologics regulations to assert authority over
cloning, and noting that, in addition to regulating tissues and manipulated cells, the
FDA has the authority to regulate both nucleic acid use in humans and the medical
devices needed to clone humans); Eibert, supra note 76, at 52 (reporting FDA
statements asserting regulatory jurisdiction over human cloning pursuant to the
FDA's statutory authority over biological products (such as vaccines and blood
products), and drugs). The BIO wrote to Donna Shalala, Secretary of the DHHS, to
suggest that the FDA has broad authority to regulate cloning as biological products.
See Stolberg, supra note 25, at A14. Historically, "biologics" referred to vaccines and
blood products, but products such as human cells and tissues that are composed of
living organisms are presently included in this category as well. See id.
42 U.S.C. § 262(i)(j) (1997). Section 262 specifically states:
The Federal Food, Drug, and Cosmetic Act [21 U.S.C.S. § 301] applies
to a biological product subject to regulation under this section, except
that a product for which a license has been approved under subsection
(a) shall not be required to have an approved application under
section 505 of such Act [21 U.S.C.S. § 355].
Id. § 262 (j). The FDA regulations on biological products, promulgated pursuant to
the PHSA, define biological products as "any virus, therapeutic serum, toxin,
antitoxin, or analogous product applicable to the prevention, treatment or cure of
diseases or injuries of man." See 21 C.F.R. § 600.3 (1996). The regulation provides a
brief description of these products as well as an interpretation of when a product is
analogous to a virus, therapeutic serum, and toxin or antitoxin. See id The
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to satisfy the statutory definition and thereby confer authority on the
FDA to regulate, the cloning procedure must involve an "analogous
product" that is utilized to prevent, treat, or cure human disease.
The FDA includes within its definition of "human cellular and
tissue-based products" a variety of "medical products derived from
the human body and used for replacement, reproductive, or
therapeutic purposes."65 For example, semen, ova, and embryos used
for reproductive purposes fall within this definition.66 In the past,
the FDA has regulated these cellular and tissue-based products on a
case-by-case basis. 67 "Some tissues have been regulated as medical
devices under section 201 of Federal Food, Drug, and Cosmetic Acte6
. . . [while] other products have been considered biological products
under section 351 of the Public Health Service Act .

.

. and drugs

under the [FFDCA]."'69 In addition, when the FDA has decided not
to regulate these cellular and tissue-based products as medical devices
or biological drugs, it has relied on § 361 of the PHSA to achieve its
regulatory purpose; this section confers authority on the agency to
prevent the spread of communicable diseases. 70 Interestingly, prior
to issuing regulations concerning "human tissues intended for
transplantation,"' 7 the FDA asserted little or no regulatory authority
over human cellular and tissue-based products.'2
regulation's language does not appear to apply to human cloning products any more
than does the statutory language. See id. Also, the inclusion of the word "injuries" in
the regulation would not apply to cloning products that would be used for
procreation, rather than for treatment of an injury. See id
165 Establishment Registration and Listing
for Manufacturers of Human Cellular
and Tissue-Based Products, 63 Fed. Reg. 26,744 (1998) (proposed rule May 14,
1998). Various tissues have already been transplanted in order to treat human
conditions, and new human cellular and tissue-based products are being developed
to treat various human ailments such as diabetes, Parkinsonism, and viral infections.
See id The FDA's position is that any "product" of somatic cell therapy "which is

applicable to the prevention, treatment, cure, diagnosis, or mitigation of disease or
injuries is a combination drug/biological product which is subject to IND
regulations." Price, supra note 28, at 639 (discussing Application of Current
Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy
Products, 58 Fed. Reg. 53,248 (1993)).
166 See 63 Fed. Reg.
26,744 (1998).

See id.
See id. Dura mater, corneas, heart valve allographs, and umbilical vein graphs
are examples of such regulated "medical devices." See id
1WId. Gene therapy and somatic cell therapy products are considered to be
biological drugs. See id.
167

168

170

See id at 26,745 (citing 42 U.S.C. § 264 (1998)). In 1993, the FDA exerted this

statutory authority to require hepatitis and HIV testing of transplantation tissue. See
id
'
21 C.F.R. § 1270 (1999).
17
See 63 Fed. Reg. at 26,745.
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In February 1997, the FDA issued two guidance documents that
replaced the current patchwork of regulatory policies with a
comprehensive new system of regulation for human cellular and
tissue-based products, and further concluded that the FFDCA and the
PHSA provided sufficient authority to accomplish this."'
In May
1998, the FDA published a proposed rule to regulate these products
in a multi-tiered, risked-based fashion. 7 4 "Minimally processed tissues
transplanted from one person to another for their normal structural
functions would be subject to infectious disease screening and testing
and to requirements for good handling procedures, but would not
need FDA premarket review or marketing approval." 75 "Cells and
tissues that are processed extensively, are combined with non-cellular
or non-tissue components, are labeled or promoted for purposes
other than their normal functions, or have a systemic effect," would
be subject to the additional, and more stringent, requirement of
premarket
approval. 6 To date, these regulations have not been
77
adopted.

If the proposed regulations are adopted and found to be an
appropriate exercise of FDA authority, human cloning products may
fall within the category of the rule requiring premarket approval of
cellular or tissue-based products that are more than minimally
manipulated.'7 8 Notwithstanding this possibility, the more difficult

175

See id. at 26,744-46.
See id.
Id. at 26,745.

176

Id

13

'7

See 63 Fed. Reg. 68,212 (1998) (reopening the comment period for
the
progosed rule).
See 63 Fed. Reg. at 26,746. The proposed rule states, in pertinent part:
Human cellular and tissue-based products subject to regulation as
biological drugs or devices are those that do not meet the criteria set
out above for regulation under section 361 of the PHS Act. That is,
they are: (1) More than minimally manipulated; (2) are promoted or
labeled for a non-homologous use; (3) have been combined with or
modified by the addition of a non-cellular or non-tissue component
that is a drug or device; or (4) have a systemic effect (except in cases of
autologous use, transplantation into a first degree blood relative, or
reproductive use).
Id. "Minimal manipulation" for cells and nonstructural tissues is defined as
"processing that does not alter the relevant biological characteristics and, thus
potentially, the function or integrity of the cells or tissues." Id. at 26,748. The FDA
defines "more than minimal manipulation" as processes that do not satisfy the
definition of minimal manipulation. See id. Genetic modification is included as an
example of manipulation not considered minimal.
See id. Nuclear transfer
technology used in cloning would entail more than minimal manipulation because
the oocyte is altered by the removal of the original haploid DNA and replaced with
1
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question is whether such cellular and tissue-based products are
sufficiently analogous to other biological products delineated in the
statute such that the FDA regulations could survive a judicial
challenge.
Human embryos produced by cloning technology,
however, do not seem to "fit" within the same scientific or medical
category as viruses, toxins, antitoxins, vaccines, serums, allergenic
products, or blood products. The statutory background, legislative
history, and resulting language of the FFDCA, the PHSA, and the
Biologics Act'" clearly demonstrate that Congress neither
contemplated the potential ramifications of human cloning
procedures nor drafted the statutory language broadly enough to
encompass such a radically new technology.'
Although embryos
produced by cloning techniques and the other biologicals
enumerated in the statute are all biologically based, there are
significant differences between them."' For example, the products
listed in § 351 of the Biologics Act are "components of a biological
entity, whereas an embryo is . . . a complete biological entity onto
itself."2' It seems unlikely that a strict interpretation of the plain

language of the statute itself would allow the FDA expansive

the diploid DNA complement from a somatic cell of another individual. See
Opposition Grows to Human Cloning on Bioethics Premise, supra note 16. "Cloning
involves removing the genetic core, or nucleus, of an egg cell and injecting into that
gutted cell the nucleus of another cell from the . . . person to be cloned." Daniel,
supra note 147, at C3. This process results in a highly manipulated cell. See id.
Gestation of implanted embryos created by somatic cell nuclear transfer techniques
also would obviously produce a systemic effect in a human recipient; however, the
regulatory language carves out an exception for cellular products used for
reproductive purposes. See 63 Fed. Reg. at 26,746. The proposal defines "transfer" as
"the placement of human reproductive cells or tissues into a human recipient." Id. at
26,750. The FDA decided that the term "reproductive use" was well understood and
chose not to define it despite the controversy surrounding the use of cloning for
human reproductive purposes. See id
19 42 U.S.C. §
262 (1994).
ISOSee PETER HuTr & RICHARD A. MERRILL, FOOD AND DRUG LAW 660-719 (1991).
181 See Price, supranote 28, at 639.
182 Id
"[I]t would be a fair construction to limit the definition of biological
products to those substances that were . . . biological components, not complete
biological entities .... [I]t seems unlikely that Congress intended, by its silence on
the subject, to take the extraordinary measure of subjecting embryos to
governmental regulation." Id The word "product" is defined as "something
produced ... by physical labor or intellectual effort... [or] a substance produced
from one or more other substances as a result of chemical change." WEBSTER'S
THIRD NEW INT'L DICTONARY 1810 (1993). A product of human cloning technology
would technically fit within this definition, but the modifier "analogous" in the
statutory provision further emphasizes, ejusdem geneis, that cloning products are not
meant to be regulated along with the other biological products specified in the
provision. See Price, supra note 28, at 639.
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jurisdiction to regulate human cloning, even though the FDA has
been inching toward this authority in the administrative arena
through its biologicals and gene therapy rules.
In addition, the FDA itself fails to support its claim of cloning
jurisdiction with any prior assertion of regulatory authority over
either in vitro fertilization or other more aggressive fertility
techniques that carry a high-risk profile."
Furthermore, the FDA
regulations and commentary dealing with human gene therapy do
not mention human reproduction despite the fact that, in February
1998, the FDA announced that these same regulations extended to
human cloning.'
The FDA has not generally claimed jurisdiction
over human reproductive methods.8 If human cloning is construed
as a new variant of a treatment for infertility, the FDA may have an
even weaker argument for regulatory authority because " [t]he FDA is
not supposed to regulate the practice of medicine," a power
traditionally entrusted to the states.""

If the courts do ultimately recognize that human cloning
products are sufficiently analogous to viruses, serums, toxins,
antitoxins, vaccines, blood products, and allergenic products such
that they fall within the statutory envelope of regulatory
consideration, the FDA first must demonstrate that these products
are "applicable to the prevention, treatment, or cure of a disease or
condition of human beings." 87 The resolution of this issue is unclear;
however, it is probably more easily addressed than the "analogous
See Daniel, supra note 147, at C3. The FDA has not attempted to regulate
in
vitro fertilization (IVF) and other infertility techniques that also involve more than
minimal manipulation of cells. See id. The FDA also has not tried to regulate
intracytoplasmic sperm injection (ICSI) procedures, an invasive modification of IVF
that carries a high-risk profile. See id. In fact, the process of a woman cloning herself
may actually be safer than IVF because there is little risk of transmitting a
communicable disease, such as AIDS, in this process. See id. "In the past, the FDA
has largely ignored the fertility industry, making no effort to regulate in vitro
fertilization . . .and other advanced reproductive technologies that have much in
common with cloning techniques." Eibert, supra note 76, at 52.
1
Greely, supra note 33, at 151. Gene therapy techniques
involve "material
manipulation of human cells that are then reinserted for medical purposes." Id.
1

185

See id.

Daniel, supra note 147, at C3 (quoting Richard Merrill,
professor at the
University of Virginia School of Law); see also United States v. Evers, 643 F.2d 1043
(5th Cir. 1981) (affirmingjudgment for defendant physician on grounds that he did
not violate § 301 (k) of the FFDCA regarding drug misbranding, and recognizing that
a licensed physician can prescribe a lawful drug for a purpose not approved by the
FDA), affg United States v. Evers, 453 F. Supp. 1141 (M.D. Ala. 1978) (declaring that
Congress did not intend the FDA to interfere with the practice of medicine and the
doctor-patient relationship).
187 42 U.S.C. § 262(i) (1990).
1
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product" analysis, and more likely to be resolved in the FDA's favor.
The issue then becomes whether human cloning products are
utilized to treat or to cure a disease or condition of human beings.
If the statutory interpretation focuses on the use of cloning
products to create a pregnancy, then assertion of regulatory
jurisdiction would fail because pregnancy is not considered a disease,
and although pregnancy arguably could be considered a human
condition, such products are not applicable to the prevention,
treatment, or cure of the "pregnancy." " Human cloning procedures
would
attempt to create a pregnancy - not to prevent, treat, or cure
s
it.i.189

The FDA could proffer a compelling argument to establish that
human cloning products would be used in many instances to treat
another disease or human condition - infertility.' 9 Under the
1
See United States v. Article of Drug (Ova II), 414 F. Supp. 660 (D.N.J. 1975),
affd mem. 535 F.2d 1248 (3d Cir. 1976). In Ova /, a case involving regulation of
pregnancy testing under the FFDCA, Judge Biunno explained:
[T]he condition of pregnancy, as such, is a normal physiological
function of all mammals and cannot be considered a disease of itself.
Pregnancy is an execution of an inherent bodily function and implies

no ailment, illness, or disease ....

A test for pregnancy, then, is not a

test for the diagnosis of disease.
Id. at 664. The court did go on to differentiate between a normal pregnancy and an
ailment or disease arising out of the pregnancy, such as a tubal pregnancy or toxemia
of pregnancy. See id The court noted, however, that these abnormal conditions,
although related to the pregnancy, must be separately diagnosed. See id In any
event, the intent of human cloning procedures would be to create a normal
pregnancy and not a disease or abnormal condition related to the pregnancy. Any
attempt to use these circumstances to pull pregnancy within the statutory language
of a disease clearly would be too far a stretch. See Price, supra note 28, at 632. Even
assuming that pregnancy created by cloning is distinguishable from pregnancy
created by sexual procreation and could be construed as a disease within the
meaning of the statute, it is clear that cloning does not to prevent, treat, or cure the
pregnancy or disease. See id If anything, cloning would attempt to create "the
disease," not prevent, treat, or cure it. See id& Although the courts have not yet
defined the scope of the term "disease" within the context of section 351 of the
PHSA, Ova II has done so in a case involving this interpretation under the FFDCA
and has determined that pregnancy is not a disease. See id. at 640. If cloning
technology was used to develop specific organs or tissues for transplantation, instead
of being used for procreative purposes, it is conceivable that these procedures would
be applicable to the prevention, treatment, or cure of disease and thereby could
confer regulatory authority on the FDA for these limited purposes. See i& at 641.
1
Human cloning procedures would be most analogous to fertility procedures.
Prevention of pregnancy is clearly contraception, not cloning, and "curing"
pregnancy could arguably encompass procedures to treat complications of
prenancy and possibly abortion, not cloning.
See WEBSTER's THIRD NEW INT'L DIaIONARY 648 (1993).

The definition of

"disease" includes "an impairment of the normal state of the living animal ... or any
of its components that interrupts or modifies the performance of the vital functions,
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Americans with Disabilities Act (ADA),191 courts have already
considered infertility to be a physical condition affecting the92
reproductive system in the context of a disability determination.'
Although "pregnancy" cannot be classified as a disease, and cloning
products cannot be considered applicable to the prevention,
treatment, or cure of pregnancy as a human condition, an implanted
human embryo created by a cloning procedure could be classified as
a biological product that is used to treat the disease or condition of
infertility.
Although the issue of whether the FDA has power to regulate
human cloning technology as biological products under the PHSA is
unclear and has yet to be determined, it seems unlikely that a court
would recognize such authority. The FDA's assertion that "analogous
biological products" include cloning products would not stand up to
judicial scrutiny because such a position would be inconsistent with
the express statutory language and legislative history of the PHSA.
Even though the FDA's biological regulations seemingly could be
construed to include human cloning within their jurisdiction, it is not
apparent that the PHSA enables the FDA to promulgate broad
regulations that encompass human cloning products.
Should
Congress decide to confer this power upon the FDA, it could do so by
simply amending the PHSA. This approach would undoubtedly have
a greater chance of success than would the direct legislative initiatives
previously discussed.
C. FDA Regulation of Cloning as a Drug
Section 201(g) (1) of the FFDCA defines the term "drug" as:
(A) articles recognized in the official United States
being a response to . . .inherent defects of the organism."

Id, One medical

dictionary defines disease as "morbus; illness; sickness; an interruption, cessation, or
disorder of bodily functions, systems, or organs." See STEDMAN'S MED. DICrIONARY 444
(25th ed. 1990); see also Katskee v. Blue Cross/Blue Shield of Neb., 515 N.W.2d 645,
651 (1994) (determining what constitutes a disease or illness in the context of health

insurance coverage). "Infertility" is defined as "the quality or state of being infertile,"
and "infertile" is defined as "not fertile or productive." WEBSTER'S, supra, at 1158.
"Sterile" is used synonymously with "infertile" and is defined as "not having or not
manifesting the power to produce offspring ...stressing some defect or lack in the
reproductive functions." Id. at 2238.
gS! 42 U.S.C. §§ 12,101-213 (1990).

192See generally Pacourek v. Inland Steel Co., 916 F. Supp. 797 (N.D.
Ill. 1996).

The Pacourek court held that infertility is a physiological disorder or condition that

affects a major life activity (i.e., reproduction), that the reproductive system is a body
system that can be impaired under the ADA, and concluded that because infertility
substantially limits reproduction, an infertile employee was disabled under the ADA.
See id. at 797, 800-04.
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Pharmacopoeia, official Homeopathic Pharmacopoeia of the
United States or official National Formulary, or any supplement
to any of them; and (B) articles intended for use in the diagnosis,
cure, mitigation, treatment orprevention of disease in man... and (C)
articles (other than food) intended to affect the structure or any

function of the body of man... and (D) articles intended for use as
a component of any article specified in clause (A), (B), or (C).1 93

Suffice it to say that human cloning products do not appear in the
cited Pharmacopoeias or National Formulary and, thus cannot be
regulated as drugs under § 201 (g) (1) (A). Whether cloning products
can be regulated as drugs under subsections (B) or (C), however,
depends on whether such products can be considered "articles" and
still remain consistent with the statutory scheme and legislative
intent.1"
The FFDCA itself provides no direct assistance in this regard
because the statute does not further explain the term "article."1 95 The
plain dictionary definition of this word is "a material thing: item,
object... [or] a thing of a particular class or kind as distinct from a
thing of another class or kind."19 This definition provides a logical,
although not very helpful, starting point for further statutory
interpretation.!
In the context of human cloning, to arguably remain applicable
to the subsequent language of the drug definition, the "article" could
only refer to the implanted product of a somatic cell nuclear transfer
procedure. 98 Under this interpretation, conferring authority upon
21 U.S.C. § 321(g)(1) (1994) (emphasis added).
1% See id.; see also Price, supra note 28, at 630.
195 See id. (noting absence of the definition of "article" in 21 U.S.C. § 321 (a)).
193

19
197

WEBSTER'S, supra note 190, at 123.

See infra notes 243-45 and accompanying text (discussing Chevron v. Natural

Resources Defense Council, Inc., 467 U.S. 837 (1984), and federal administrative
agency construction of statutory provisions); see also MCI Telecomm. Corp. v.
American Tel. & Tel. Co., 512 U.S. 218 (1994) (critiquing the use and limitations of
dictionary definitions in statutory interpretations and finding that the relevant time
for determining legislative intent of statutory language is the time that the
controlling statute was enacted).
198 See Price, supra note 28, at 630.
Price argues that an embryo produced by
cloning technology could not constitute an "article" within the meaning of the
FFDCA. See id. By interpreting the statute to include human cloning products as
articles and thereby granting the FDA power to regulate them as drugs, the FDA
would be able to license cloned human embryos and require pre-procedure
approval. See id. Price posits that this would empower the FDA to pre-approve the
creation of human life, a scenario neither contemplated by Congress nor impliedly

approved of by legislative silence on the issue. See id That Congress has
independently proposed several bills to limit or ban human cloning procedures
would support this premise. See supra notes 111-47 and accompanying text
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the FDA to license, pre-approve, or otherwise regulate human
cloning products as drugs would raise significant constitutional
questions as to whether the FDA's regulatory jurisdiction could
permissibly include a fundamental procreative liberty.'9
These
questions, however, would present themselves regardless of which
avenue the FDA chose in regulating human cloning. To overcome
this constitutional impediment to agency regulation, the FDA would
likely argue the existence of a compelling state interest in the safety
of the embryo and/or born-alive, cloned person.2w
Another substantial challenge the FDA would need to address is
the agency's "historical failure to assert jurisdiction over embryos
created in other ways," including in vitro fertilization.20 1 The FDA
(discussing legislative responses to human cloning).
199 See Price, supranote
28, at 630.
See supra note 149 and accompanying text (discussing constitutionally
protected rights and liberties involving procreation and possible compelling
governmental justifications to regulate in the human cloning context). A state may
restrict abortions after fetal viability "as long as the law contains exceptions for
pregnancies which endanger a woman's life or health." Planned Parenthood v.
Casey, 505 U.S. 833, 846 (1992). Casey further held that "the [s]tate has legitimate
interests from the onset of pregnancy in protecting the health of the woman and the
life of the fetus that may become a child." Id. Considering the high failure rate of
present-day cloning attempts, human cloning procedures could not conceivably be
considered safe for the cloned embryo. See supra note 17 (discussing high failure
rate of cloning attempts); see also Andrews, supra note 76, at 664-69 (discussing the
constitutional issues revolving around procreative liberties and the regulation of
human cloning); supra notes 63-67 and accompanying text (postulating physical and
genetic dangers to the subsequently cloned individuals); supra notes 73-75, 79-81 and
accompanying text (discussing potential psychological harm to cloned offspring). At
present, the unknown physical dangers to successfully cloned individuals and the
foreseeable psychological harms to them would likely be construed as compelling
governmental interests to satisfy any constitutional concerns over restricting
reproductive liberties. See NBAC REPORT, supra note 1, at F-6. By contrast, any
statutory scheme infringing on fundamental procreative rights would be subject to
strict scrutiny and could fall outside of Congress's commerce power. See Price, supra
note 28, at 631. But see F.D.C. Reports, 60 "the Pink Sheet" No. 35, Aug. 31, 1998, at
5. The safety of the abortifacent RU-486 was not considered with respect to an
unborn child carried by a woman taking the drug because the FDA is required by
statute to ensure that drugs are safe and effective for their intended use. See id.
Because the intended user of RU-486 is a pregnant woman seeking a termination of
pregnancy, the safety and efficacy for the embryo need not be evaluated by the
agency. See id,
201 Price, supra note 28, at 630-31. Price stated that the FDA never believed
it had
regulatory authority over matters such as in vitro fertilization, artificial insemination,
traditional sexual intercourse, or other methods of human reproduction. See id.
Price cites several congressional hearings held in the 1980s that addressed the low
success rates of fertility clinics, and that subsequently led to the Fertility Clinic
Success Rate and Certification Act of 1992 (codified at 42 U.S.C. §§ 263 (a) (1)-(7)).
See i& at 631. The Centers for Disease Control (CDC) became the federal agency
responsible for the Act's implementation; the FDA was never mentioned during this
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would be hard-pressed to justify a position asserting agency authority
over human cloning when it has not previously expressed an interest
in regulating other reproductive technologies that utilize similar
techniques.
Furthermore, FDA efforts to regulate cloning and other
reproductive techniques may exceed agency authority because such
efforts could easily be construed as attempts to regulate the practice
of medicine.2 The line between in vitro fertilization regulation and
the regulation of human cloning techniques, if the line exists at all,
would be a blurred one regardless of how the FDA attempts to justify
its authority over cloning.
Assuming that Congress intended to include human cloning
products within the meaning of "articles" under the FFDCA (which is
an arguably easier determination to reach than considering cloning
products as "analogous products" under the PHSA), a reviewing
court would then need to decide if these "cloning articles" were
either "intended for use in the diagnosis, cure, mitigation, treatment
or prevention of disease," or "intended to affect the structure or

process as having jurisdiction over fertility clinic procedures. See id
M
See supra note 186 (discussing the FDA's lack of authority to regulate the
practice of medicine); see also HuTr & MERRILL, supra note 180, at 619-21 (discussing
Legal Status of Approved Labeling for Prescription Drugs; Prescribing for Uses
Unapproved by the Food and Drug Administration: Notice of Proposed Rule
Making, 37 Fed. Reg. 16,503 (1972)). In discussing the scope of § 505 of the FFDCA,
the rule proposal sets out, in pertinent part:
[T]he new drug provisions apply only at the moment of shipment in
interstate commerce and not to action taken subsequent to shipment
in interstate commerce .... The 1948 [Miller] amendment did not...
extend the reach of the new drug provisions of the Act ... to action
taken after interstate shipment ....
Once the new drug is in a local pharmacy after interstate
shipment, the physician may, as part of the practice of medicine,
lawfully prescribe a different dosage for his patient, or may otherwise
vary the conditions of use from those approved in the package insert,
without informing or obtaining the approval of the Food and Drug
Administration ....
...The physician is then responsible for making the final judgement
as to which, if any, of the available drugs his patient will receive ....
...
[T]he Act does not require a physician to file an investigational
new drug plan before prescribing an approved drug for unapproved
uses or to submit ...

data concerning the therapeutic results and the

adverse reactions ....
I& at 619-20. Although the FDA did not take final action on the proposal, the agency
considers the substance of the rule proposal as its established policy. See iti at 621
(citing "Use of Approved Drugs for Unlabelled Indications," 12 FDA DRUG BuLL. 4
(Apr. 1982)).
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function of the body."' ' The analysis of whether cloning products
would be used in the "diagnosis, cure, mitigation, treatment, or
prevention of disease""' closely parallels the previous discussion
concerning analogous biological products "applicable to the
0 5°
prevention, treatment, or cure of a disease" under the PHSA.
Because the intended use of cloning products would be to create,
and not to treat, diagnose, or prevent a pregnancy, and because
pregnancy is not considered by the courts to be a disease, 06 then, ipso
facto, the assertion of FDA jurisdiction over human cloning under
this analysis would fail. In addition, unlike the biological products
provisions of the PHSA, the FFDCA does not include "human
conditions" within its targeted scope of regulatory authority,27 thus
any further argument forjurisdiction is defeated.
As under the biological products provisions of the PHSA, a
better argument for FDA regulatory authority under the FFDCA
would be that cloning products are articles intended for use in the
treatment of infertility. 28 The same general analysis would apply in
this context and could possibly permit a court, liberally interpreting
congressional intent, to find the necessary statutory authority for FDA
regulation of human cloning as a drug.
Regarding the issue of whether cloning products could be
construed as drugs "intended to affect the structure or any function
of the body," °' a court must first determine if the cloning articles
would be "inserted in, injected in, ingested by or applied to the
body." '10 The in vivo act by a physician of physically implanting the
Price, supra note 28, at 631 (quoting 21 U.S.C. § 321 (g)(1) (B) & (C)).
21 U.S.C. § 321 (g)(1)(B) (1994).
205 42 U.S.C. § 262(i)
(1997).
20
See supra note 188 (discussing Ova II, as well as the possible use of cloning
techniques to develop tissues or organs (interpreted as products or articles) for
transplantation, thereby possibly satisfying the statutory requirement of treating,
curing, or mitigating disease).
207
Compare21 U.S.C. § 321(g) (1) (B) (1994) (containing the term "disease" in this
FFDCA provision) with 42 U.S.C. § 262(i) (1997) (including the phrase "disease or
condition of human beings" in this PHSA provision).
2W See supra notes 190-92 (suggesting that infertility may be
included within the
definition of disease).
21 U.S.C. § 321(g)(1)(C) (1994).
21
Ova I, 414 F. Supp. at 666 (D.N.J. 1975). "In the ordinary sense of the word
'drugs,' it would be rational to limit its meaning to items used or applied for
diagnostic purposes to those employed 'in vivo' and not for those employed 'in
vitro.'" Id. at 663. "The [ ] definition, articles intended to affect the structure or any
function of the body is obviously not applicable to any article which is used 'in vitro'
and in no way inserted in, injected in, ingested by, or applied to the body." Id. at 666.
Although actual formation of the embryo by means of somatic nuclear cell transfer
203
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embryo created by in vitro cloning technology into the uterus of a
and subsequent birth would likely satisfy this
woman for gestation
2 11
requirement.
The question then becomes whether implantation of the cloned
embryo would be intended to "affect the structure and function of
the body."" There is little dispute that pregnancy has such effects on
the human body. Although the primary purpose of a cloning
procedure would clearly be to bring the implanted embryo to term, 1
the cloning "article" or "drug" would also be implanted with the
intent to affect the structure and function of the woman's body in
order to allow such gestation to continue. The statute, however, does
not specify that only one intended use of the article is permissible or
that the purpose to be regulated must be the primary intended use.
In this case, the article's intent to affect the structure and function of
the body complements the primary purpose of allowing the cloned
individual to be born. Acceptance of this line of reasoning could also
mean that implanted embryos that were created through artificial
insemination or through in vitro fertilization techniques would also
be subject to FDA regulation as drugs that potentially require
"premarketing" approval.1 4 As previously stated, this is an area that
the FDA has chosen not to regulate.1 5
Although the FDA could make several plausible arguments to
justify its authority to regulate human cloning as a drug, it would have
to overcome a series of statutory obstacles to achieve that jurisdiction.
Furthermore, the FDA has not established its authority to regulate
other reproductive technologies. 6 One leading expert on food and
would occur in vitro, the end product of this procedure would be inserted or

implanted into the woman for gestation, arguably, in many circumstances, to treat
infertility and to affect the structure and function of the woman's body to allow her
to carry the cloned individual to term.
211 See STEDMAN'S MED. DIcroNARY 769-70 (25th ed. 1990). STEDMAN'S defines
"implant" as "[t]o graft or insert... [to] transplant." Id. at 769. "Implantation" is
defined as "[a]ttachment of the fertilized ovum (blastocyst) to the endometrium,
and its subsequent embedding in the compact layer." Id. at 770.
212 See Price, supranote 28, at 633.
213

214

See id.
See id.

25 See supra note 201 and accompanying text (discussing
the FDA's lack of
reulatory history with human reproductive technologies).
16 See generally Jay M. Zitter, Annotation, What Is "Drug"
Within Meaning of §

2

01(g)(1) of Federal Food, Drug, and Cosmetic Act (21 U.S.C.A. § 3 2 1(g)(1)), 127 A.L.R.
FED. 141 (1998). In discussing the extensive case law relating to the regulation of
drugs by the FDA, including drugs directed at the reproductive system, no cases
involved the regulation of human reproductive technologies, cloning technologies,
or infertility procedures. See id. Likewise, no cases deal with the regulation of

20001

HUMAN CLONING

drug law has concluded that the FDA clearly does not possess the
power to regulate the practice of medicine.""7 These additional
obstacles to FDA regulation should prove insurmountable.
D. IDA Regulation of Cloning as a MedicalDevice
Section 201 (h) of the FFDCA defines the term "device" as:
an instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article,
including any component, part or necessary, which is: (1)
recognized in the official National Formulary, or the United
States Pharmacopeia ... (2) intended for use in the diagnosis of
disease or conditions, or in the cure, mitigation, treatment, or
prevention of diseasein man... or (3) intended to affect the structureor

any function of the body of man. . . and which does not achieve its
primary intendedpurposes through chemical action within or on the
body of man . . . and which is not dependent upon being

metabolized for achievement of its primary intended purposes. 218
As previously noted, human cloning products are not listed in the
National Formulary or United States Pharmacopeia; thus, any analysis
pursuant to this language may be quickly dismissed.
Upon further review of the statutory language, human cloning
products would most closely be analogous to "implants" or "other
similar or related articles." 9 The analysis of whether cloning
products could be considered "articles" mirrors the reasoning
employed when considering cloning products as drugs.no With
regard to medical devices, however, the scope of the term "article" is
narrowed considerably by use of the modifiers "similar or related,"
thereby compelling a more limited categorization of cloning
products - "articles" referring to instruments, apparati, implements,

cloning or reproductive technologies as new drugs under the FFDCA. See generallyJay
M. Zitter, Annotation, What Is "New Drug" Within Meaning of § 201(p) of FederalFood,
Druq and Cosmetic Act (21 U.C.S.A § 321(p)), 133 A.L.R FED. 229 (1997).
See Daniel, supra note 147, at C3 (quoting Professor Richard Merrill as stating
that "[t]he FDA is not supposed to regulate the practice of medicine"); see also supra
note 186 (discussing FDA authority to regulate the practice of medicine); United
States v. Evers, 643 F.2d 1043 (5th Cir. 1981) (concluding that off-label use of
prescription drugs by physicians is not prohibited by the FDA); United States v.
Evers, 453 F. Supp. 1141 (M.D. Ala. 1978) (finding that the FDA does not regulate
the practice of medicine).
2
21 U.S.C. § 321(h) (1994) (emphasis added).
219 See
id.
22
See supranotes 194-200 and accompanying text (discussing the characterization
of human cloning products as "articles" under 21 U.S.C. § 321(g)(1) and the
constitutional issues raised by such a classification).
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machines, contrivances, in vitro reagents, or implants.2' The common
sense understanding and everyday use of these terms dictates that any
further consideration of this issue must focus on cloning products as
implants - a seemingly plausible interpretation.22
If human cloning products are considered implants for purposes
of the statute, then it must be determined whether these "cloned
implants" were "intended for use in . . . the cure, mitigation,
treatment or prevention of disease ... or [were] intended to affect
the structure or function of the body."' ' This statutory language
regarding a medical device is very similar to that of the FFDCA drug
provision and PHSA biological product provision. 4 Section 201 (h)
2
See CHARLES L. KNAPP & NATHAN M. CRYSTAL, PROBLEMS IN CoNTRAcT LAw
422
(3d ed. 1993). The maxim "ejusdem generis" instructs that "a general term joined with
a specific one will be deemed to include only things that are like (of the same genus
as) the specific one." Id. This "usually leads to a restrictive interpretation." Id. Price
suggests that inclusion of a "laundry list" of articles, expressly delineated in the
medical device provision, illustrates congressional intent to restrict the term "similar
or related articles" to tangible, commercial items. See Price, supra note 28, at 634.
Assuming, arguendo, that this is true, human embryos created by cloning
techniques, like other present-day embryo donation arrangements, may, in some
situations, be commercial in nature and thus satisfy this requirement.
M See supra notes 210-11 and accompanying text (discussing the
medical
definition of the term "implant" and its possible relation to the use of human cloning
procedures for the treatment of infertility).
One medical dictionary defines
"implant" as "an object or material, such as an alloplastic or radioactive material or
tissue, partially or totally inserted or grafted into the body for prosthetic, therapeutic,
diagnostic, or experimental purposes." DORLAND'S ILLUSTRATED MED. DICIONARY
824 (27th ed. 1988). "Implantation" is also defined as "the insertion of an organ or
tissue ... in a new site in the body [and] the insertion or grafting into the body of
biological, living, inert, or radioactive material." Id.
22 21 U.S.C. § 321(h) (2) & (3) (1994).
Several courts have also interpreted this
statute. See, e.g., United States v. Article of Device, 731 F.2d 1253 (7th Cir. 1984).
The Seventh Circuit, in Article of Device, found that (1) instruments used in research
are considered "devices" if the intended use includes the diagnosis and treatment of
disease or other human conditions; (2) the instruments "need not be the only agent
in the curative process"; and (3) instruments used in research are not excluded from
the "device" definition because they may threaten the public health during the
investigation phase. Id. Other federal courts have addressed similar issues. See, e.g.,
Alabama Tissue Ctr. Of Univ. of Ala. Health Serv. Found., P.C. v. Sullivan, 975 F.2d
373 (7th Cir. 1992) (concluding that a human heart valve allograft that is processed,
preserved, and stored prior to implantation into a human recipient is an implant
within the meaning of the medical device provisions). The court in Alabama Tissue
rejected the argument that the definition of "device" only includes man-made or
artificial implants. See id. at 378. However, the court also noted that heart-valve
allografts undergo a cryopreservation process allowing for a considerable shelf life
and appear to be artificial "implants" in accordance with a permissible statutory
interpretation by the FDA. See id. Interestingly, frozen embryos also have an

extended "shelf-life," and there is no reason to believe frozen embryos created by
somatic cell nuclear transfer technology would be any different.
2
See 221 U.S.C. § 321(h) (1997); 21 U.S.C. § 321(g)(1) (1997); 42 U.S.C. §
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refers to medical devices "intended for use in the diagnosis of disease or
conditions or in the cure, mitigation, treatment, or prevention of
disease.''2 s Section 201 (g) (1) defines "drugs" as "articles intended for
use in the diagnosis, cure, mitigation, treatment or prevention of
disease."m Essentially, the medical device provision separates the
language concerning "diagnosis" (of disease or conditions) from that
relating to "treatment or prevention" (of disease).2" By contrast, the
drug definition groups the term "diagnosis" with the "treatment or
prevention" language (referring to disease only) .2 Because human
cloning products would have no practical application to the diagnosis
of a disease or condition, including pregnancy as a condition, the
language at variance is of no relevant significance. The question of
whether the FDA has regulatory authority over human cloning under
either provision is limited to whether cloning products would be
intended to cure, mitigate, treat, or prevent a human disease.2 A
similar approach would also be logical under the PHSA, which
likewise refers to biological products as "applicable to the prevention,
'
treatment, or cure of a disease or condition of human beings. 2
Any proposed regulation of human cloning technology would be
primarily targeted at attempts to create a pregnancy and to bring that
pregnancy to term. Any attempt to regulate human cloning that
characterizes cloning products as "being used in the treatment of
pregnancy as a disease" would fail because courts have already made
it clear that pregnancy is not a disease. 23 ' The same argument made
under the biological products and drug provision discussions,
however, would be applicable to the consideration of cloning
products as medical devices intended for use in the treatment of
infertility as a disease. 232 A court, conceivably, could find an
262(i) (1997).
22

21 U.S.C. § 321(h) (1997) (emphasis added).
21 U.S.C. § 3 21(g)(1) (1997) (emphasis added).

See Price, supra note 28, at 635. The 1976 Medical Device Amendments added
the terms "in vitro reagent" and "or other conditions" to bring the regulation of
pregnancy test kits within the scope of FDA authority. "[I ] n vitro reagents intended
to diagnose 'conditions' such as pregnancy are now considered 'medical devices'
under section 201(h)(2)." Id. For a discussion regarding the 1976 Medical Device
Amendments and their relation to the Ova II case and regulation of pregnancy test
kits, see Hur

& MERRILL,

supra note

21 U.S.C. § 3 21(g)(1).
See Price, supra note 28, at 635.
230 42 U.S.C. § 262(i)
(1997).
23
See supra notes 188-89, 206
proclamation that pregnancy is not a
2
See supranotes 190-92, 208 and
of the term "disease" may encompass

180, at 746-47.

22

and accompanying text (discussing judicial
disease).
accompanying text (positing that the definition
infertility).
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implication of congressional intent to confer authority upon the FDA
to regulate human cloning products as implants intended for use in
the treatment of infertility.
Another question is whether human cloning products could be
regulated as medical devices because they "affect the structure or any
function of the body." The medical device definition is the same as
the drug definition in § 201 (g) (1) (c), except that it adds the phrase
"which does not achieve its primary intended purposes through
chemical action within or on the body of man or other animals and
which is not dependent upon being metabolized for the achievement
of its primary intended purposes. '"m The primary intended purposes
of human cloning articles and implants would be to affect the
structure or function of the woman's body in order to bring the
Recognizing that "primary intended
cloned embryo to term.2M
purposes" is set forth in the plural and that the phrase also refers to
effects upon any function of the body, this terminology alone should
not pose a bar to regulation. However, the language of exclusion for
devices that are dependent upon chemical action or metabolism for
their effect does create an uncertainty for proponents of regulatory
jurisdiction under this provision. This additional language specifies
that the intended effect of the implanted cloned embryo must be
"accomplished through mechanical rather than chemical or
physiological means.',2 5 Although an implanted embryo causes
distinct physical changes in the woman's body to allow gestation to
continue, it is unlikely that these physical changes would equate to
mechanical action and still remain faithful to congressional intent.
The effect that an implanted embryo has upon the structure or
function of the body more likely would be described as physiological
or chemical (i.e., hormonal).2m
Even though credible arguments could be advanced to justify
regulation of human cloning products as medical devices (i.e.,
implants) intended for use in the treatment of the human disease of
infertility, 37 there are additional roadblocks to regulation. One
233

21 U.S.C. § 321 (h) (3) (1994).

See supra notes 209-15 and accompanying text (discussing regulation of cloning
articles as drugs intended to "affect the structure or any function of the body").
235 Price, supra note 28, at 638. Price notes that medical devices, unlike drugs, "do
234

not achieve their primary purpose through chemical action or metabolism." Id
236 See id.
237 See Hurr & MERRiLL, supranote 180, at 745-46, 752-57 (discussing 1976 Medical
Device Amendments and establishment of three classes of medical devices).
Considering the uncertainties of human cloning and the widely debated safety
concerns of such procedures, any finding of FDA regulatory authority over human
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problem is that, as noted above, the FDA has not previously asserted
jurisdiction over other human infertility procedures. The FDA also
clearly lacks regulatory authority over the practice of medicineYm
The uncertainty regarding the interpretation of statutory language
and of congressional intent, the constitutional concerns with respect
to procreative liberties, the lack of FDA regulatory precedent in the
field of infertility procedures, and the lack of FDA authority to
regulate medical practice all combine to preclude any attempts to
regulate human cloning as a medical device.
CONCLUSION

In reflecting on the moral, ethical, and political considerations
involving the issue of human cloning, the first question that comes to
mind is why the FDA would want to assert regulatory authority in this
controversial area.!" The FDA might have been searching for an
efficient way, at least in the United States, to impede the seemingly
hasty efforts of human cloning mavericks such as Richard Seed.
Another explanation may lie in the FDA's desire to expand its
regulatory jurisdiction unencumbered by often poorly drafted and
politically influenced statutory language.24 ' As noted in the discussion
regarding legislative attempts to ban the cloning of human beings,
such congressional efforts at legislation might very well inhibit, or
ban completely, important scientific research that utilizes cloning
techniques to treat a variety of human maladies.2 4 The FDA might

cloning pursuant to the medical device section of the FFDCA would require the
designation of cloning technology as Class III medical devices. See id. Such
classification would require submission of an application to the FDA, prior to use in
the marketplace, demonstrating the safety and efficacy of the procedures. See id. In
finding that a human replacement heart valve allograft was a medical device, the
Alabama Tissue court declared that "the Supreme Court[] has allowed liberal
construction of the FDC Act consistent with its purpose of protecting the public
health." See Alabama Tissue Ctr. of Univ. of Ala. Health Serv. Found., P.C. v.
Sullivan, 975 F.2d 373, 378 (7th Cir. 1992) (citing United States v. 25 Cases, More or
Less, of an Article of Device, 942 F.2d 1179, 1183 (7th Cir. 1991)). "The FDA has
consistently interpreted 'device' in a very expansive manner." Id. (quoting 25 Cases,
942 F.2d at 1182 (internal quotations omitted)).
See supra notes 185-86, 214-17 and accompanying text (discussing failure of the
FDA to assert authority over reproductive technologies and lack of FDAjurisdiction
over the practice of medicine).
239 See Price, supra note
28, at 628.
24 See id.
241 See idi at
629.
242 See id.; see also supra notes 40-43, 52-58 and accompanying text
(discussing the
application of cloning technology to produce new medicines, develop tissues and
organs for transplantation, and advance primordial stem-cell research).
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want to avert this possibility by assuming regulatory control. One
final reason, perhaps, is that the FDA believes that it possesses the
expertise and resources to regulate this high-profile area more
effectively than can present-day or newly contemplated governmental
bodies.
Whether the FDA can sustain its assertion of jurisdiction over
human cloning technology will likely depend on a judicial
If a reviewing
interpretation of the agency's enabling statutes.2
court determines that "Congress has not directly addressed the
precise question at issue," as is clearly the case with cloning, "the
court [will] not simply impose its own construction on the statute, as
would be necessary in the absence of administrative interpretation."04
When a statute is ambiguous or silent on the matter in dispute, the
judicial inquiry becomes "whether the agency's answer is based on a
permissible construction of the statute."2" Agency interpretation of a
statutory provision is entitled to substantial deference. 2 " In addition,
courts historically have permitted Congress to delegate rulemaking
without finding that such
authority to administrative agencies
delegation offends the United States Constitution.4
243

See 42 U.S.C. § 262 (1998); 21 U.S.C § 321 (g)(1) (1994); 21 U.S.C. § 321(h)

(1994).
244 Chevron v. Natural Resources Defense Council, Inc., 467 U.S. 837, 842-43
(1984).
245 Id.
246 See id. at 843. "Legislative regulations are given controlling weight unless they
are arbitrary, capricious, or manifestly contrary to the statute. Sometimes the
legislative delegation to an agency on a particular question is implicit rather than
explicit." Id. Congress inadvertently or intentionally may not resolve competing
interests, instead leaving resolution of the issues to "the agency charged with
administration of the statute in light of everyday realities." Id. "When a challenge to
an agency's construction of a statutory provision.., centers on the wisdom of the
agency's policy, rather than whether it is a reasonable choice within a gap left open
by Congress, the challenge must fail." Id. The Seventh Circuit has also found that an
agency's interpretation of its own regulation will be sustained unless it is clearly
erroneous or inconsistent with the regulatory language. See Wisconsin Elec. Power
Co. v. Reilly, 893 F.2d 901, 907 (7th Cir. 1990).
247 See WILLIAM F. FUNK ET AL., ADMINISTRATIVE PROCEDURE AND PRACIGE,
471-74
(1997).
Until the 1930s, the United States Supreme Court rejected all
nondelegation challenges. See id. at 472. In 1935, the Court invalidated two statutes
at 472-73 (discussing Panama Refining Co. v. Ryan, 293 U.S.
on this ground. See id&
388 (1935) and A.L.A. Schechter Poultry Corp. v. United States, 295 U.S. 495
(1935)). Since then, all nondelegation challenges have been rejected, although the
doctrine has been used to "justify narrowly interpreting an agency's statutory
authority." Id. at 472.
248 U.S. CONST. art. I, § 1 (providing that legislative powers
are vested in
Congress); U.S. CONST. art. I § 8 (authorizing the delegation of rulemaking to
agencies because Congress may enact "all laws which shall be necessary and proper").
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Assertion of regulatory authority by an agency like the FDA,
however, is not without bounds. For example, in Brown &?Williamson
Tobacco Corp. v. FDA,249 the FDA attempted to expand the scope of its
jurisdiction by regulating tobacco products under the "device"
provision of the FFDCA.2 In characterizing the FDA actions as an
attempt to introduce an entirely new regime of regulation not
established by Congress, the Fourth Circuit rejected the FDA's
interpretation of the enabling statute and held that the FDA, "[b]y its
ultra vires action,

.

.

. exceeded the authority granted to it by

Congress., 25'

Thus, the court invalidated the FDA's rulemaking
action.2-52 It is likely that other courts, for the exact same reasons,
would take a similar stance on FDA assertion of jurisdiction over
human cloning procedures.
The fact that congressional attempts have been made to directly
legislate in this politically charged area evinces a lack of intent to
delegate authority over cloning issues to the FDA. Because it appears
that Congress itself could not come to a final consensus on this issue,
it is unlikely that it would acquiesce to FDA authority over cloning.255
Courts undoubtedly would be confronted with the significant
challenge of attempting to determine what the legislature would have
intended had it contemplated the concept of human cloning when it
enacted the FFDCA and the PHSA.
Another question that arises is what entity or person would
challenge the FDA's assertion of regulatory authority in this area.
Surely a scientist, such as Richard Seed, who is enjoined from the
practice of cloning human beings would have standing. 54 Congress
itself may take offense to the FDA's assertions and may elect to hold
congressional hearings on this matter. In addition, couples denied
access to human reproductive cloning procedures might mount a
constitutional challenge to FDA attempts to prohibit such efforts.255
The remaining question is whether the reach of FDA authority
249
250

153 F.3d 155 (4th Cir. 1998).
See Coynne Beahm, Inc. v. FDA., 958 F. Supp. 1060, rev'd 153 F.3d 155 (4th Cir.

1998) (detailing the FDA proffer that cigarettes are combination products consisting
of the drug nicotine and a nicotine-delivery device).
251 Brown & Williamson Tobacco Corp. v. Food and Drug Admin., 153 F.3d 155,
176 (4th Cir. 1998).
252 See
id.
253 See, e.g., Armey, supra note 146 (quoting House
Majority Leader Dick Armey as
rejecting the concept of FDAjurisdiction over cloning).

See supra note 24 and accompanying text (reporting on Seed's statements
rearding an intent to challenge FDAjurisdiction).
25

See supra note 149 (discussing potential constitutional violations regarding
the

regulation of privacy rights or liberty interests in the area of procreative decisions).
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over human cloning is too far a stretch. Although authority to
regulate human cloning is a gray area, and although it would be
difficult to determine if such authority exists, it is unlikely that the
FDA would survive a serious challenge to its purported authority. In
order to prevail, the FDA will need to address constitutional
challenges and obtain favorable interpretations of the statutory
language of the FFDCA or the PHSA, as well as the congressional
intent underpinning these statutes. Such judicial interpretations
would further be complicated by ethical considerations and public
policy concerns. The most serious impediment to FDA authority,
however, would be the inescapable conclusion that the FDA does not
possess the authority to regulate the practice of medicine, an area
into which cloning technology that is used to create life would clearly
fall.One last perspective worthy of discussion is whether the FDA
should regulate human cloning at all. FDA regulation would insulate
science and its accompanying research initiatives from the political
issues encountered during past legislative attempts to ban human
cloning.5 7 Embarking on this route to agency regulation would allow
certain cloning research to continue, yet would preclude the cloning
of entire human beings.
It would also avoid much of the
controversial public debate between the scientific community and the

256

See supra notes 185-86, 214-17, 238 and accompanying text (discussing the

FDA's failure to establish jurisdiction over other reproductive technologies, and the
lack of FDA authority to regulate human cloning as a drug, device, or biological
product because the agency lacks authority to regulate the practice of medicine).
27 See Paul Berg & Maxine Singer, Regulating Human Cloning,
ScIENCE, Oct. 16,
1998. Berg, the director of the Beckman Center for Molecular and Genetic
Medicine at Stanford University, and Singer, president of the Carnegie Institution of
Washington, concluded:
[W]e are concerned that anticloning legislation will resurface in
Congress. Sensitive and flexible guidelines overseen by an interagency
regulatory body, including the Food and Drug Administration, NIH,
and representatives of the general public, would be better than
legislation - an approach that avoids the potential delays and vagaries
of the legislative process, encourages research, and fosters public
engagement.
Id. But see Annas, supra note 13, at 124-25. Annas prefers a broad-based agency
composed almost exclusively of nonphysicians and nonresearchers to "oversee
human experimentation in the areas of genetic engineering, research with human
embryos, xenografts, artificial organs, and other potentially dangerous boundarycrossing experiments." Id. at 124. In this way public values, rather than parochial
concerns, are protected. See id&"The suggestion that the... FDA can substitute for
such an agency is fanciful. The FDA has no jurisdiction over either the practice of
medicine or human replication and is far too narrowly constituted to represent the
public in this area." Id. at 125.
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pro-life constituency.ss In addition, regulatory schemes, unlike rigid
statutory mandates, are flexible and can adapt to changing science
and technology while utilizing agency expertise in the process.' The
benefits of human cloning regulation under the auspices of the FDA
or an FDA-like agency are apparent.m It is now incumbent upon
Congress to empower such an agency to carry out this important
function in a sensible, well-informed, and nonpartisan manner.
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Seesupra notes 112 and 129.
See Greely, supra note 33, at 151-52. "Legislatures may be able to set general

policies, but the proposed human cloning bans provide a nice study of what can
happen when legislatures refuse to delegate the implementation of such regulation
to expert agencies." I& at 152.
2W
See Andrews, supra note 67, at B4. Andrews identified the "need to create a
governmental body with the authority to license fertility clinics, assess what
reproductive technologies may be safely offered and by whom, and require the
collection of follow-up data on the children created by these technologies." Id
Andrews preferred the British regulatory model over FDA or Congressional cloning
bans. See ii An independent agency similar to the FDA should be established to
assess all cloning research. See Wilmut, supra note 6, at 74. Another regulatory
model was created by the Department of Health and Human Services in the mid1970s to regulate recombinant DNA experiments, which at that time were thought of
as risky. See Greeley, supra note 33, at 151. This model, the Recombinant Activities
Committee (RAG), is now concerned primarily with human gene therapy and has
been proposed as a means to regulate human cloning. See id. "Unlike the FDA, the
RAC undertakes an open process, including public meetings at which objections,
both scientific and ethical, to pending protocols are often aired." Id. Ruth Macklin
of Albert Einstein College of Medicine supported an FDA-like regulatory scheme to
oversee research, including experiments on human cloning. See F.D.C. Reports, 9
HEALTH NEws DAILY, No. 52, Mar. 18, 1997, at 5. Macklin explained, "[Slince there is
nothing analogous to the FDA, we might want to put something like that in place...
[t]here should be something analogous to the structure that exists for drugs and
devices that would have to govern cloning research." Id. (internal quotations
omitted). NBAC member Carol Greider speculated that a scheme similar to the
NIH's RAC model might be appropriate to oversee human cloning research. See id.

